Doc Lab Inc. / Protocol Number 22-UPHUV-01 Page 1 of 11
INFO RME D  CO NSENT F O RM
AND
AUTH O RIZATI O N T O  USE AN D  D IS C L O SE PR O TE C TE D  HEALTH INF O RMATI O N
Sponsor / Study Titl e :
Proto c ol Nu m b er :
Princ ipal In ve stigato r :
(Study D o c to r )
Telephone:
Address:Doc Lab In c . / “ C lini c al Utility o f  a P C R Test f or the
Management o f  C ompli c ated Urinary Tra c t In f e c tions in
Adults”
22-UPHUV - 01
Micha e l Aber g er, M. D .
(816) 232 - 8877
(816) 244 - 5273 (24 - Hour)
Phoe ni x  Urolo g y
[ADDRESS_149532]. Joseph, M O  [ZIP_CODE]
KEY INF O R M ATI O N
You are invited to take part in a researc h  s t ud y .  Th i s  re s e a rc h  s t ud y a im s  to ev a l ua te cli n ical
utility o f urine polymerase chain reactio n  ( P C R )  te s t for t h e m ana geme n t of pa tie n t s  wit h
complicate d  urinary tract infection (cU T I ).  Doc L ab  I n c .  i s  sp o ns ori n g t h i s  re s e a rc h  s t ud y .
This d o cument outlines the purpose, proce du re s , and  an y p o ss i b le ri s k s  or b e n efit s  of t h e
research study. T he study staff will also ex p l a i n  t h i s  cli n ic a l re s e a rc h  s t ud y to yo u  and  c an
answer any questions that you may have ab o u t t h e s t ud y, i n cl ud i n g t h i s  d oc u me n t .  Y o u  ha ve
been pr o vided with a copy of this docume n t to review b efore m a ki n g yo u r d eci s io n  w h et h er t o
participate in this research or not. Ple as e t a ke yo u r time to re ad  t h i s  d oc u me n t c a ref u lly .  Th is
document may contain words you do n ot und er s t and ; yo u  a re e n co u r a ge d  to as k qu e s tio ns  of
the study staff, and/or anyone else that yo u  feel comfort ab le wit h  b efore m a ki n g yo u r d ecisi on
whether o r not to participate in this re s e a rc h.
·This is a research study and y ou r pa rtici pa tio n  i s  vol un t a ry .
·This research study is to evaluate cli n ic a l u tility of molec u l a r d i a g n o s tic met h o ds , a  P C R
test, in providing medical care to adu lt pa te n t s  wit h  cU T I b y com pa ri n g t h e d i a g n ostic
and therapeutic result of P C R te s t to u ri n e c u lt u re and  s e ns itivity (C&S)  te s t .
·The study compares the urine P C R te s t and  t h e tr ad itio na l u ri n e C&S  te s t .
·The main risk you should be aw a re of i s  ass oci a te d  wit h  p er s i s te n ce of cU T I .
·There is no guarantee that yo u  will b e n efit from yo u r pa rtici pa tio n  i n  t h i s  s t ud y .
Information learned from the s t ud y m a y h el p  ot h er p eo p le i n  t h e f u t u re .  Po ss i b le
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-01 Page 2 of 11
benefits of taking part may be a  qu icker and  f u ll recovery from yo u r c u rre n t i n fecti on
epi[INVESTIGATOR_17110].
·This study is for research purpo s e s  o n ly .  Th e s t ud y i s  n ot i n te nd e d  to subs tit u te a
routine care, but to identify a met h o d  to a c h ieve a  qu icker d i a g n o s i s  and  f u ll recovery .
BACK G R O UN D  AN D  PURP O SE
You are bei n g asked to participate in t h i s  re s e a rc h  s t ud y b ec aus e yo u  a re p re s e n ti n g s ym p t o ms
of co mplic a ted urinary tract infection .
The purp o se of this research study is to:
·Eval u ate diagnostic efficiency o f u ri n e P C R te s ti n g w h e n  com pa re d  to tr ad itio na l u ri n e
cultu re and sensitivity.
·Eval u ate the clinical utility of u ri n e P C R re su lt s  i n  an ti b iotic s electio n  w h e n  com pa re d  t o
traditional urine culture and se ns itivity .
·Eval u ate the clinical utility of u ri n e P C R re su lt s  i n  t h e s t ud y d octor’ s  cli n ic a l d eci s ion
making when compared to tra d itio na l u ri n e c u lt u re and  s e ns itivity .
The study will compare the two diagn os tic met h o ds , a  u ri n e P C R and  a  u ri n e C&S , for d i a gn o sis
and further the treatment of cU T I. A u tili za tio n  of u ri n e P C R te s t i s  app rove d  b y t h e U n ite d
States F ood  and Drug Administration (F DA )  for d i a g n o s i s  and  tre a tme n t of u ri na ry tr a ct
infecti o n. However, the use of the P C R s t ud y d evice as  d e s cri b e d  i n  t h i s  s t ud y d e s ig n , i s
investigati o nal. An investigational use i s  o n e t ha t i s  n ot app rove d  b y t h e F DA .
Appr ox imately 720 sub j ects will partici pa te i n  t h i s  s t ud y .
WHAT WILL HAPPEN D URIN G  THE STU D Y ?
Your participation in this study will last app roxim a tely 28 da y s  and  will i n cl ud e app roxim a tely 2
study visits to the study site.
Screening:
Visit 1 –  S c r ee ning ( D ay 0)
Befo re any study - related tests and proce du re s  a re p erforme d , yo u  will b e as ke d  to re ad  a n d
sign this c o nsent document. T he followi n g s cree n i n g te s t s  and  p roce du re s  will t h e n  b e
perfo rmed to determine if you are eligi b le to t a ke pa rt i n  t h i s  s t ud y:
·Y o u will be asked to provide demogr aph ic i n form a tio n  su c h  as  yo u r s ex, a ge, and  d ate of
birth
·Study staff will ask about your h e a lt h  s t a t us , me d ic a l h i s tory, and  an y me d ic a tio ns  or
treatments that you take or h a ve receive d  i n  t h e pas t
·Study staff will collect your vital s ig n  (b o d y tem p er a t u re, h e a rt r a te and  b loo d  p re ssu re ) ,
and may conduct physical e x ami na tio n
·Y o u will be asked to provide a u ri n e sa m p le
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-01 Page 3 of 11
·Once this visit is complete, you will b e p rovi d e d  wit h  i ns tr u ctio ns  o n  t h e n ext s te ps  t o
take
This study will use competitive enrollme n t .  Th i s  me ans  t ha t w h e n  a  t a rget nu m b er of sub jects
begins the s tudy, all further enrollme n t will b e clo s e d.  Th erefore, it i s  p o ss i b le t ha t yo u  co u l d  b e
in the screening phase, ready to begin t h e s t ud y, and  b e d i s co n ti nu e d  wit h o u t yo u r co ns ent i f
the target n umber of sub j ects has alre ad y b eg un  t h e s t ud y .
Study Treatment:
This is a ra n domized study. T his mea ns  yo u  will b e r and omly ass ig n e d  b y c han ce ( like t h e fli p  of
a coin) t o  receive either a diagnosis an d  tre a tme n t g u i d e d  b y u ri n e P C R te s t or b y u ri n e C&S.
You will have a 50% (1 in 2) chance to b e ass ig n e d  to t h e P C R -a rm and  a  50% ( 1 i n  2 )  c han ce t o
be assigned to the C & S- arm. T he study d octor will o n ly ha ve a cce ss  to t h e re su lt of yo u r
assigned - test after the end of the stu d y .  I n  c as e of emerge n cy, h owever, t h e s t ud y d octor c an
get this information.
You will have the following study visit s  and  und ergo t h e followi n g p roce du re s :
Visit 2 –  Study T re at me nt ( D ay 0 [gi ve  or take 5 days])
·This visit may be conducted virt ua lly or m a y b e co ndu cte d  o n  t h e sa me da y of s cree n i n g
·Study staff will confirm if you are eligi b le to pa rtici pa te i n  t h e s t ud y
·Y o u will be asked about any c han ge s  i n  yo u r h e a lt h , and  ab o u t an y me d ic a tio ns , or
treatments taken since the last vi s it
·Y o ur study doctor will use the re su lt of t h e te s t for t h eir cli n ic a l d eci s io n  m a ki n g and  t o
provide you with the best medic a l c a re
Visit 3 –  End - of - Study ( D ay 28 [gi ve  o r  take 7 days])
·This visit marks the end of yo u r pa rtici pa tio n  to t h i s  s t ud y
·Y o u will be asked to return to t h e s t ud y s ite a fter app roxim a tely 28 da y s  from yo u r
baseline visit
·Y o u will be asked about any c han ge s  i n  yo u r h e a lt h , and  ab o u t an y me d ic a tio ns , or
treatments taken since the last vi s it
·Study staff will collect your vit a l s ig ns  (b o d y tem p er a t u re, h e a rt r a te and  b loo d
pressure), and may conduct a ph y s ic a l ex a mi na tio n
·Y o u will be asked to provide a u ri n e sa m p le for re p e a t u ri n e te s t s
After Study T reatment:
If yo ur c o ndition persists or worsens, yo u r s t ud y d octor will co n ti nu e to p rovi d e c a re to yo u.
Unsc hedul e d V isit:
You may contact [CONTACT_39635]/st ud y s t a ff if yo u  ha ve an y co n cer ns  or n otice c han ge s  i n
your healt h ; or study staff may contact [CONTACT_132334] u  w h e n  add itio na l ass e ss me n t s  a re n ee d e d.  Y o u  m a y
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-01 Page 4 of 11
be asked to attend additional remote ass e ss me n t s  or re p e a t l ab or a tory te s t s  if re qu e s te d  b y
the study doctor.
EXPE C TATIONS
·If you participate in this study, yo u  will b e ex p ecte d  to und er s t and  t h e re s e a rc h  s t ud y
and provide voluntary, written i n forme d  co ns e n t
·Be willing and able to complete a ll s t ud y ass e ss me n t s  and  re qu ireme n t s , i n cl ud i n g
availability for follow - up for t h e du r a tio n  of t h e s t ud y
·Tell the study staff about any c han ge s  i n  h e a lt h  or p ro b lem s  yo u  m a y ex p erie n ce
·Ask questions of the study sta f f as  yo u  t h i n k of t h em and  e nsu re yo u r o n goi n g
understanding
·Tell the study staff if you change yo u r mi nd  ab o u t yo u r pa rtici pa tio n  i n  t h i s  s t ud y
Subj e c t Responsibiliti e s:
If yo u participate in this study, you will b e ex p ecte d  to:
·Be a ged 18 and above at the time of co ns e n t
·Be p resenting at least two new, p er s i s te n t or wor s e n i n g cU T I s ig ns  and  s ym p tom s  at t h e
screening visit
·Be s u spected or confirmed to h a ve p y u ri a  (pus  i n  yo u r u ri n e )
·H ave cU T I that requires microbiologic a l d i a g n o s i s  and  tre a tme n t as  susp ecte d  b y t h e
study doctor
·Pre s ent active signs of U T I that f a ile d  to re s olve o n  fir s t - li n e t h er ap y or i d e n tifie d  a s a
high - risk patient population
·Be a ble to provide at least 8 mL of u ri n e (ab o u t 2 te asp oo ns)  a t V i s it 1 and  3
·Be willing to abstain from se xua l i n terco u r s e or us e co nd om s  du ri n g an y s ex ua l cont a ct
until the End of S tudy (EO S ) Vi s it i s  com p lete
·Must be able to read and write i n  En gli sh  (su rvey s  a re n ot a v a il ab le or v a li da te d  i n  a n y
other language than English)
·Must not be enrolled in, or partici pa te i n  an ot h er i n terve n tio na l cli n ic a l tri a l wit h i n  30
days  prior to the S creening Vi s it
·Must not be using or have used an y an ti b iotic s  for an y cli n ic a l i nd ic a tio n , ot h er t han  U T I
·Must not have used any antibiotic s  for t h e tre a tme n t of U T I wit h i n  48 h o u r s  b efore t h e
study baseline urine sample is o b t a i n e d
·Must not have any fetal congenit a l an om a ly ( for ex a m p le, ge n etic abn orm a lity or m ajo r
congenital malformation) ide n tifie d  o n  an te na t a l u ltr as o und , if p reg nan t
·Must not have any rapi[INVESTIGATOR_132322] i n g d i s e as e or imme d i a tely life - t h re a te n i n g ill n ess,
including acute hepatic failure, or re sp ir a tory f a il u re
·Must not have any medical con d itio n  or ot h er f a ctor t ha t i n  t h e j ud gme n t of t h e s t ud y
doctor might affect ability to c o m p ly wit h  p roce du re s
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-01 Page 5 of 11
RISKS, SI D E EFFECTS, AN D / O R D ISC O MF O RTS
There are no additional risks of harm wit h  pa rtici pa ti n g i n  t h i s  re s e a rc h  s t ud y .  Th e p re s e n te d
investigati o ns and management strategie s  a re a ll pa rt of ro u ti n e o p tim a l c a re .  Th e i d e n tifi ab le
risks that are associated with cU T Is have b ee n  li s te d.  Th e s e ri s k s  i n cl ud e bu t a re n ot limite d  t o :
·Bur n ing sensation or urgency w h e n  u ri na ti n g
·Yea s t infection (vaginitis/vulv o v a gi na l c and i d i as i s)
·Pr o gression or relapse of cU T I
·Allergic reaction to antimicrobi a l t h er ap y, i n cl ud i n g s ym p tom s  of naus e a , vomiti n g,
headache, skin rash and anap h yl a xi s , a  s evere, p ote n ti a lly life - t h re a te n i n g a llergic
reaction.
·Pr o gression to acute renal fail u re
·Cl os tridioides difficile ( C . diff) i n fectio n , w h ic h  i s  i n fl a mm a tio n  of t h e colo n  c aus e d  by
[CONTACT_132335] a.
·Sep s is, which is a serious conditio n  i n  w h ic h  t h e b o d y re sp o nds  im p ro p erly to an
infection, causing inflammation t h ro u g h o u t t h e b o d y .  Th i s  ty p e of i n fectio n  c an  c a use
damage to multiple organ system s , le ad i n g t h em to f a il, s ometime s  eve n  re su lti n g i n
death.
There is a p o ssibility that your cU T I d o e s  n ot get b etter .
There may be other unknown risks.
There is mi n imal potential risk of loss o f p riv a cy and  lo ss  of co n fi d e n ti a lity, and  m u lti p le
precauti o ns will be in place to protect yo u r p riv a cy .  However, abs ol u te co n fi d e n ti a lity c anno t
be guaranteed.
ALTERNATI V ES T O  PARTICIPATI O N
You d o  n o t h ave to be in this study to receive tre a tme n t for yo u r u ri na ry tr a ct i n fectio n.  Y o u  c an
receive available routine medical care if yo u  d o n ot wi sh  to b e i n  t h i s  re s e a rc h  s t ud y .  Ple as e t a lk
to the study doctor about your optio ns  b efore yo u  d eci d e w h et h er or n ot yo u  will t a ke pa rt i n
this study.
NEW FIN D IN G S
Any new important information that is d i s covere d  du ri n g t h e s t ud y and  w h ic h  m a y i n fl u e n ce
your willingness to continue participatio n  i n  t h e s t ud y will b e p rovi d e d  to yo u.
BENEFITS
You may benefit as a result of your partici pa tio n  i n  t h i s  s t ud y .  Th ere i s , h owever, n o g ua r an tee
that y o u will benefit from your particip a tio n  i n  t h i s  s t ud y .  I n form a tio n  le a r n e d  from t h e s tu d y
may help o ther people in the future.
COM PENSATI O N F O R PARTICIPATI O N
You will n o t receive any monetary com p e nsa tio n  for yo u r pa rtici pa tio n  i n  t h i s  s t ud y .
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-[ADDRESS_149533] ud y will b e h el d  co n fi d e n ti a l exce p t w h e n  sha ri n g t h e
informati o n is required by [CONTACT_132336] s cri b e d  i n  t h i s  i n forme d  co ns e n t .  Th e s t ud y d octor ( s ) , t h e
spons o r o r p ersons working on behalf of t h e sp o ns or, and  und er cert a i n  circ u m s t an ce s , t h e
[LOCATION_002] F ood and Drug Administr a tio n  (F DA )  and  t h e I ns tit u tio na l Review Bo a r d  ( IRB) will
be able t o  inspect and copy confidenti a l s t ud y - rel a te d  recor ds  w h ic h  i d e n tify yo u  b y na me. Th is
means that absolute confidentiality ca nn ot b e g ua r an tee d.  If t h e re su lt s  of t h i s  s t ud y a re
published or presented at meetings, yo u  will n ot b e i d e n tifie d.
A descripti o n of this clinical trial will b e a v a il ab le o n  h tt p : // www .C li n ic a l T ri a l s. gov, as  re qu ire d
by U.S. Law. T his Web site will not incl ud e i n form a tio n  t ha t c an  i d e n tify yo u.  At mo s t, t h e We b
site will include a summary of the res u lt s.  Y o u  c an  s e a rc h  t h i s  We b  s ite a t an y time .
Your study records including confidenti a l i n form a tio n  ab o u t yo u  collecte d  du ri n g t h e s t ud y will
be kept at a secure location.
While every effort will be made to protect t h e p riv a cy of yo u r i n form a tio n , abs ol u te
confidentiality cannot be guaranteed. Th i s  d oe s  n ot limit t h e du ty of t h e re s e a rc h er s  and  o t h ers
to pr o tect your privacy.
By [CONTACT_132337], yo u  co ns e n t to t h e collectio n , a cce ss , us e a n d
discl o sure of your information as descri b e d  ab ove .
COM PENSATI O N F O R INJURY
If yo u bec o me ill or are in j ured while yo u  a re i n  t h e s t ud y, get t h e me d ic a l c a re t ha t yo u  n ee d
right away. Y ou should inform the he a lt h c a re p rofe ss io na l tre a ti n g yo u  t ha t yo u  a re
participating in this study. If you tell the s t ud y s t a ff t ha t yo u  t h i n k yo u  ha ve b ee n  i n j u re d  t h e n
they will help you get the care you nee d.
If yo u are i nj ured from procedures do n e for t h e pu r p o s e of t h i s  s t ud y, t h e sp o ns or will pa y fo r
those medical e x penses necessary to tre a t yo u r i n j u ry t ha t a re n ot covere d  b y yo u r me d ical
insurance or any other third - party cover a ge .  By s ig n i n g t h i s  d oc u me n t, yo u  will n ot lo s e a ny of
your legal rights or release anyone involve d  i n  t h e re s e a rc h  from re sp o ns i b ility for mi s t a kes .
To pay medical e x penses, the sponsor will n ee d  to k n ow s ome i n form a tio n  ab o u t yo u  like y ou r
name, date of birth, and Medicare Be n efici a ry I d e n tifier ( MBI ).  Th i s  i s  b ec aus e t h e sp o ns or ha s t o
check t o  see if you receive Medicare and  if yo u  d o, re p ort t h e pa yme n t it m a ke s  to Me d ic a re .
COSTS
Regular medical e x penses will apply f o r yo u r me d ic a l c a re .  Y o u  m a y b e re qu ire d  to bu y
medicati o n s  prescribed to you which yo u  m a y n ee d  to t a ke a t h ome as  i ns tr u cte d.  Th ere will b e
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-[ADDRESS_149534] questions, concerns or complaint s  ab o u t t h e s t ud y su c h  as :
·Wh o m to contact [CONTACT_132338] o f a  re s e a rc h- rel a te d  i n j u ry or ill n e ss ;
·Payment or compensation for b ei n g i n  t h e s t ud y, if an y;
·Y o ur responsibilities as a researc h  sub ject;
·Eligi b ility to participate in the s t ud y;
·The study doctor ’s or study site ’ s  d eci s io n  to wit hd r a w yo u  from pa rtici pa tio n ;
·Results of tests and/or proced u re s ;
Please c ontact th e  study docto r  at th e  telephone number listed on the f irst pa g e o f  this
consent do c u me nt .
If yo u seek emergency care, or hospi[INVESTIGATOR_132323] n  i s  re qu ire d , a lert t h e tre a ti n g ph y s ici an  t ha t y ou
are particip a ting in this research study .
An instituti o nal review board (IRB) is an  i nd e p e nd e n t committee e s t ab li sh e d  to h el p  p rotect t h e
rights o f re s earch sub j ects. If you have an y qu e s tio ns  ab o u t yo u r rig h t s  as  a  re s e a rc h  sub ject,
contact:
·By m ail :
Study S ub j ect Adviser
Advarra IRB
[ADDRESS_149535] . , Su ite 600
Columbia, MD [ZIP_CODE]
·o r c a ll toll f ree : 877 - 992 - 4724
·o r by [CONTACT_111327] : [EMAIL_2656]
Please reference the following number w h e n  co n t a cti n g t h e S t ud y Sub ject A d vi s er:
Pro00071764.
VOLUNTARY PARTICIPATI O N / W ITHDRAWAL
Your decision to participate in this st ud y i s  vol un t a ry .  Y o u  m a y c h oo s e to n ot pa rtici pa te or y ou
may withdr a w from the study for any re as o n  wit h o u t p e na lty or lo ss  of b e n efit s  to w h ic h  y ou
are o therwise entitled and without any effect o n  yo u r f u t u re me d ic a l c a re .  However, p le as e
note that t h e F DA requires that any inform a tio n  collecte d  up  to t h e p oi n t of yo u r wit hd r a w a l
cann o t be removed from the study.
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-01 Page 8 of 11
The study d octor or the sponsor can sto p  yo u r pa rtici pa tio n  a t an y time wit h o u t yo u r co ns e n t
for the f o llowing reasons:
·If it a ppears to be medically harmf u l to yo u ;
·If you fail to follow directions for pa rtici pa ti n g i n  t h e s t ud y;
·If it is discovered that you do not meet t h e s t ud y re qu ireme n t s ;
·If the study is canceled; or
·F o r administrative reasons.
If yo u leave the study for any reason, t h e s t ud y d octor m a y as k yo u  to ha ve s ome e nd- of -s t ud y
tests f o r y ou r safety.
PRIM ARY HEALTH CARE PR OV I D ER NOTIFI C ATI O N O PTI O N
I consent t o  having my family doctor or p rim a ry h e a lt h  c a re p rovi d er n otifie d  b y t h e s t ud y s ite
of my participation in this study and/ o r an y s ig n ific an t fi nd i n g s  rel a te d  to my h e a lt h  (p le as e
check yes o r no).
YES (If yes, please complete the inform a tio n  b elow )
N O
Name [CONTACT_132375] o r o r primary health care
provider:
Teleph on e and F a x  Number:Name:
[CONTACT_132376] :
Tel:
Fax:
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-[ADDRESS_149536]’s Printed Name
_________ _ _____________________ _________
Subj ect’s Signature___________
Date
_________ _ _____________________ _________
Printed Name [CONTACT_132377] C onducting t h e
Consent D i s cussion
_________ _ _____________________ _________
Signature o f the Person C onducting t h e
Consent D i s cussion___________
Date
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-[ADDRESS_149537] the study. Health data may include:
· Your name.
· Address.
· Phone number.
· Date of birth.
· Medical history.
· Information from your study visits, including all test results.
Health data may come from your study records or from existing records kept by
[CONTACT_132339].
For this study, the study staff may share health data about you with authorized
users. Authorized users may include:
· Representatives of Doc Lab Inc.
· Representatives of 10343781 Canada Inc (dba dicentra CRO).
· Representatives of Advarra IRB (an Institutional Review Board that reviews
this study).
· The Food and Drug Administration (FDA) and other US federal and state
agencies.
· Government agencies to whom certain diseases (like HIV, hepatitis, and
STDs) must be reported.
· Governmental agencies of other countries.
· Outside individuals and companies, such as laboratories and data storage
companies, that work with the researchers and sponsor and need to access
your information to conduct this study.
· Other research doctors and medical centers participating in this study, if
applicable.
· A data safety monitoring board which oversees this study, if applicable.
Your health data will be used to conduct and oversee the research, including for
instance:
· To see if the study intervention works and is safe.
· For other research activities related to the study intervention
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / Protocol Number 22-UPHUV-01 Page 11 of 11
Once your health data has been shared with authorized users, it may no longer be
protected by [CONTACT_132340].
Your permission to use and share health data about you will end in 50 years
unless you revoke it (take it back) sooner.
You may revoke (take back) your permission to use and share health data about
you at any time by [CONTACT_132341]. If you do this, you will not be able to stay in this study. No new
health data that identifies you will be gathered after your written request is
received. However, health data about you that has already been gathered may
still be used and given to others as described in this form.
Your right to access your health data in the study records will be suspended
during the study to keep from changing the study results. When the study is over,
you can access your study health data.
If you decide not to sign this form, you will not be able to take part in the study.
STATEMENT OF AUTHORIZATION
I have read this form and its contents were explained. My questions have been
answered. I voluntarily agree to allow study staff to collect, use and share my
health data as specified in this form. I will receive a signed and dated copy of this
form for my records. I am not giving up any of my legal rights by [CONTACT_3368].
__________________________________
Printed Name [CONTACT_3385]
__________________________________
Signature [CONTACT_3385]__________
Date
Michael Aberger, M.D. Advarra IRB Approved Version 22 May 2023 Revised 6 Jun 2023
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
CLIN I CAL PROTOCOL COVER PAGE
Protocol Title:
Protocol Num b er:
Protocol Date:
Vers io n :
Stud y De s ig n :
Spon s or:
CRO:Clinical Utility o f a P CR Te s t for the M anagement of Complicated
Urinary Tract I n fection s  in Adult s
22-U P HUV-[ADDRESS_149538], S uite 400
Hills boro, Oregon, [ZIP_CODE]
10343781 Canada Inc. (dba dicentra CRO)
603-7 S aint Thoma s  S treet
Toronto, Ontario, M 5 S  2B7
Canada
UPH-STD-05-01
Vers i on:  [ADDRESS_149539] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 1 o f  44
Page 1 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
Protocol Sig n at u re s :
Partie s Name S ig n at u re Date
Spon s or:
Doc Lab Inc. Roel  Chavez 06  /  27  /  2…
[ADDRESS_149540], S uite 400
Hills boro, Oregon, [ZIP_CODE]
Principal In ve s tigator:
Thoma s  H u ard, P hD
Doc Lab Inc.
[ADDRESS_149541], 06  /  27  /  2…
PhD
Site I nve s tigator:
Protocol Revi s io ns :
Vers ion De s cri p tio n  of C h a n ge s
#
0 OriginalDate S ig n at u re
06/23/23
UPH-STD-05-01
Vers i on:  [ADDRESS_149542] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 2 o f  44
Page 2 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
Table of Co n te n t s
1.LIST OF  ABBREVIATION S  ..... . ........................................................................................... [ADDRESS_149543] Enrollment............... . .................................................................................... . .... 19
7.2. Te s ting S ite S etting .............. . .................................................................................... . .... 19
7.3. S tudy Arm s ..................................................................................................................... 20
7.4. Randomization .......................................................................................................... . .... 20
7.5. Blinding and Unblinding...... . ......................................................................................... 20
8. STUDY VI S IT S ................................................................................................................. 20
8.1. P re- s creening.................................................................................................................. 20
8.2. Vi s it 1 - S creening and Ba s eline (Day 0).................................................................. . .... 21
8.3. Vi s it 2 - Treatment (Day 0 + 5)...................................................................................... 21
8.4. Vi s it 3 - End-of- S tudy (Day 28 ± 7) ......................................................................... . .... 22
UPH-STD-05-01
Vers i on:  [ADDRESS_149544] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 3 o f  44
Page 3 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
9.AS S E SSM ENT S  AND P ROCEDURE S .......................................................................... . .... 23
9.1. Urine S ample Analy s i s ......... . ......................................................................................... 23
9.2. Body Temperature................ . .................................................................................... . .... 24
9.3. Blood P re ss ure and Heart Rate....................................................................................... 24
9.4. P hy s ical Examination........... . .................................................................................... . .... 24
9.5. Termination of the S tudy...... . ......................................................................................... 24
10. SAFETY IN S TRUCTION S  A N D GUIDANCE ............................................................... 24
10.1. D efinition s  of Adver s e Event s  (AE s ) .................................................................... . .... 25
10.2. Collecting, Recording, an d  Reporting of AE s ............................................................ 25
10.3. O bligation s  of the S pon s or ......................................................................................... 27
10.4. A dver s e Event s  M onitoring........................................................................................ 27
10.5. U n s cheduled Vi s it s ........... . .................................................................................... . .... 27
11. STATI S TICAL EVALUATIO N ....................................................................................... 27
11.1. Sample S ize ................................................................................................................ 27
11.2. Study P opulation............... . .................................................................................... . .... 28
11.3. A naly s i s  P lan ......................................................................................................... . .... 28
11.3.1.
11.3.2.
11.3.3.
11.3.4.
11.3.5.
11.3.6.Analy s i s  P opulation... . ......................................................................................... 28
Primary and S econdary Endpoint s ................................................................. . .... 28
Statis tical Analy s i s  of the P rimary Endpoint ...................................................... 29
Discordant Analy s i s  on the Re s ult s  of M olecular ver s u s  Conventional M et h ods
30
Exploratory Inve s tigation s  .................................................................................. 30
Data Analy s i s  of S eco n dary Endpoint s ............................................................... 31
12. PR O TOCOL DEVIATION( S ). . ......................................................................................... [ADDRESS_149545] of the S tudy...................................................................................... 31
14.2. I RB Approval ........................................................................................................ . .... 32
14.3. I nformed Con s ent F orm (IC F ).................................................................................... 32
14.4. Ri s k s  and P rocedure s  to M inimize Ri s k................................................................ . .... 32
15. QUALITY A SS URANCE AND QUALITY CONTROL................................................. 33
UPH-STD-05-01
Vers i on:  [ADDRESS_149546] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 4 o f  44
Page 4 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
15.1. A uditing and In s pecting.... . ......................................................................................... 33
15.2. Study M onitoring.............. . .................................................................................... . .... 33
15.2.1.
15.2.2.Respon s ibilitie s  of the Inve s tigator( s )................................................................. [ADDRESS_149547] KEE P ING ............................................................. 34
16.1. Confidentiality....................................................................................................... . .... 35
16.2. Source Data and S ource Document s  ..................................................................... . .... 35
16.3. Ca s e Report F orm s  (CR Fs )......................................................................................... 35
16.4. D ata s torage and Acce ss ... . ......................................................................................... 35
16.5. D ata Quality A ss urance .... . ......................................................................................... 36
17. REFERENCE S  .................................................................................................................. 37
18. AP P ENDICE S  ................................................................................................................... 38
Appendix I.
Appendix II.
Appendix III.Treating Inve s tigator Que s tionnaire ................................................................ 38
Urine S ample Collection ................................................................................. 39
Device s pecification: pathogen target s  and Cq range s , antibiotic s  re s i s tance
gene s  and Cq range s .................................................................................................................. 40
Appendix IV. Comparator te s t re s ult s .................................................................................... 41
UPH-STD-05-01
Vers i on:  [ADDRESS_149548] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 5 o f  44
Page 5 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
1. L I ST OF ABBREV I AT I ONS
AE Adver s e Event
CFU Colony- F orming Unit
CKD Chronic Kidney Di s ea s e
Cq Quantitative Cycle
CRF Ca s e Report F orm
CRO Clinical Re s earch Organization
CTMS
cUTI
CVA
C&S
DBP
DOB
Df
eCRF
EDA
EDC
EOS
ET
FCl
GCP
H0
H1
HIPAA
Hpf
HR
IB
ICF
ICH
IFU
IRB
ITT
Mod-ITT
NCS
OTC
PCR
PD
PI
[INVESTIGATOR_132324] M anagement S oftware
Complicated Urinary Tract Infection
Costovertebral Angle
Culture and S en s itivity
Diastolic Blood P re ss ure
Date of Birth
Degree of F reedom
Electronic Ca s e Report F orm
Exploratory Data Analy s i s
Electronic Data Capture ( P latform)
End of S tudy
Early Termination
Favorable Clinical Outcome
Good Clinical P ractice
Null Hypothe s i s
Alternative Hypothe s i s
Health In s urance P orta b ility and Accountability Act
High P ower F ield
Heart Rate
Inves tigator’ s  Brochure
Informed Con s ent F orm
International Council for Harmonization
Instruction for U s e
Institutional Review Board
Intention-to-Treat
Modified Intent-To-Treat P opulation
Not Clinically S ignificant
Over-the-Counter
Polymera s e Chain Reaction
Protocol Deviation
Principal Inve s tigator
Polycy s tic Kidney Di s ea s e
Protocol Violation
UPH-STD-05-01
Vers i on:  [ADDRESS_149549] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 6 o f  44
Page 6 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
RT-PCR Rever s e Tran s cripta s e Polymera s e Chain Reaction
SAE S eriou s  Adver s e Event
SBP S y s tolic Blood P re ss ure
SIV S ite Initiation Vi s it
SOP S tandard Operating P rocedure
TAT Turnaround Time
TEAE Treatment Emergent Adver s e Event
TLF Table s , Li s ting s  and F i g ure s
UTI Urinary Tract Infection
WBC White Blood Cell
UPH-STD-05-01
Vers i on:  [ADDRESS_149550] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 7 o f  44
Page 7 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
2. PROTOCOL S UMMARY
2.1. Syn ops i s
Title
Protocol Nu m b er
Stud y Ce n ter( s )
Stud y De s ig n
Sam p le Size
Stud y Objective s
Stud y Pop u latio n
UPH-STD-05-01
Vers i on:  [ADDRESS_149551] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C [ADDRESS_149552] Infection s  in Adult s
22-U P HUV-01
At lea s t 6 s tudy s ite s  located in the United S tate s
Multi-center, r andomized, parallel-a ss ignment, open-label, clinical
utility s tudy
N=720 (120 per s ite)
Primary O b jective:
· To evaluate patient s ' s ymptomatic re s pon s e s  following diagno s is and
treatment ba s ed on the re s ult s  of the molecular method ver s u s  those
from the conventional urine culture method
Seco nd ary O b jective s :
· To determine the efficacy of antibiotic s election u s ing molecula r
method ver s u s  the conventional urine culture method
· To a ss e ss  clinical utility of P olymera s e Chain Reaction ( P CR)
result s  during the clinical deci s ion-making pha s e in patient care
· To compare the availability of the antimicrobial s u s ceptibility
information from molecular te s ting and conventional te s ting at the
time of initial antimicrobial therapy
· To quantify the overall agreeability between the diagno s tic re s ults
generated by P CR ver s u s  Culture and S en s itivity (C& S )
Adult patients with s u s pected* Complicated Urinary Tract Infections
(cUTI)
*Symptomatic patient s  with evidence of pyuria AND at higher ri s k f o r
Urinary Tract Infection (UTI) complication s . In thi s  s tudy, patient
population co ns idered at higher ri s k are:
1) Elderly ( ≥65 year s ) or;
2) M ale o r ;
3) Pregnant or;
4) Recurrent UTI – defined a s  multiple occurrence ( ≥3) of
uncomplicated or complicated UTI in pa s t 12 month s , de s pi[INVESTIGATOR_132325];
5) Underlying co-morbiditie s : metabolic di s order (e.g. diabete s ),
immuno s uppre ss ion, or impaired renal function (e.g. chronic
kidney di s ea s e (CKD)) or;
Page 8 o f  44
Page 8 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
6) Known functional and anatomic abnormalitie s  of the urinary
tract (e.g. s tone s , s tent s , recent in s trumentation, indwelling
catheter s , neurogenic bladder, or polycy s tic kidney di s ea s e
(PKD) )  or;
7) Per s i s tent infection after primary antibiotic therapy
Inclus io n  Criteria Subject s  mu s t meet all of the following c r ite r ia to be con s ide r ed
eligible fo r  admi ss ion to the s tudy:
I1. At lea s t 18 year s  of age at the time of con s ent;
I2. P re s e n ting at lea s t two of the following new, per s i s tent or
wors ening cUTI s ign s  and s ymptom s  at s creening vi s it:
a) fever (temperature >38 degree s  Cel s iu s  or >100.4 degrees
Fahrenheit), hypothermia (temperature <35.5 degree s  Celsius
or <95.9 degree s  F ahrenheit), rigor s , or chill s
b) dy su ria, urinary frequency, urgency, or hematuria
c) sup r apubic pain or pelvic pain
d) co s tovertebral angle (CVA) tenderne ss
e) nau s ea or vomiting
f) radi o graphic evidence of pyelonephriti s
g) leu k ocyto s i s
I3. Urine s pecimen with evidence of pyuria
a) dipstick analy s i s  po s itive for nitrite and/or leukocyte
estera s e, or;
b) ≥10 white blood cell s  (WBC s ) per cubic millimeter [mm 3 ] ,
or;
c) ≥10 WBC s  per high power field (hpf), or;
d) clinically s u s pected pyuria (e.g. change in urine color,
sediment in urine, or foul- s melling urine)
I4. Having cUTI that require s  microbiological diagno s i s  and
treatment a s  s u s pected by [CONTACT_132342] s tigator;
I5. P re s enting active UTI that failed to re s olve on fir s t-line the r apy
or ide n tified a s  a high-ri s k* patient population;
*High - ri s k patient population include tho s e who are elderly
(≥65year s ), male, pregnant, having recurrent UTI ( ≥3/year),
with underlying co-morbiditie s  (e.g. diabete s ,
immuno s uppre ss ion, or CKD), or with known functional and
anatomical abnormalitie s  of the urinary tract (e.g. s tone s , s tents,
recent in s trumentation, indwelling catheter s , neurogenic
bladder, or P KD)
I6. Able t o  provide at lea s t 8 mL urine at vi s it 1 and 3;
UPH-STD-05-01
Vers i on:  [ADDRESS_149553] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 9 o f  44
Page 9 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
I7. Willi n g to ab s tain from s exual intercour s e or u s e condom s
durin g  any s exual contact [CONTACT_132343]-of- S tudy (EO S ) vi s it is
complete;
I8. Willi n g to comply with protocol requirement s , including
availability for follow-up for the duration of the s tudy.
Excl us io n  Criteria Subject s  meeting any of the following c r ite r ia will not be eligible f o r
admi ss ion to the s tudy:
E1. Unable or unwilling to provide written informed con s ent;
E2. Unable to read and write in Engli s h ( s urvey s  are not available
or validated in any other language than Engli s h);
E3. Currently participating in or ha s  participated in an
interventional clinical trial with an inve s tigational product o r
device within 30 day s  prior to the S creening Vi s it;
E4. Currently on or chronic u s e of any antibiotic s  for any clinical
indication, other than UTI (refer to s ection 6.3.);
E5. Recei p t of any do s e of a potentially therapeutic oral or s y s temic
antibi o tic s  for the treatment of UTI within 48 hour s  before the
study ba s eline urine i s  obtained
E6. P regnant women with known fetal congenital anomaly (e.g.,
genetic abnormality or major congenital malformation)
based on antenatal ultra s ound;
E7. Any rapi[INVESTIGATOR_132326] s ea s e or immediately life-
threatening illne ss , including acute hepatic failure, or
respi[INVESTIGATOR_1399]
E8. M edical condition or other factor that in the judgment o f  the
inves tigator might affect ability to comply with proced ur es.
Stud y Duratio n
Stud y End p oi n t sThe duration of s tudy participation for each enrolled patient i s
approximately 28 day s .
Primary E ndp oi n t:
· Number (and percentage) of patient s  in each s tudy arm with
favorable clinical outcome s * at the EO S  vi s it
*favorable clinical outcome s  are defined a s  a clinical re s pon s e o f
improvement a and/or cure b
a Clinical improvement i s  defined a s  1) Re s olution of cUTI s igns
and s ymptom s  pre s ent at ba s eline, 2) Development of no new c U T I
symptoms and/or 3) Avoidance of parenteral antibiotic therapy ,  in
or out of ho s pi[INVESTIGATOR_307], at any time after randomization
b Clinical cure i s  re s olution of all acute s ign s  and s ymptom s  of
cUTI and improvement to s uch an extent that no further
UPH-STD-05-01
Vers i on:  [ADDRESS_149554] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 10 o f  44
Page 10 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
antimicro b ial therapy (IV or oral) i s  required for the treatment o f
the cUTI
Seco nd ary En dp oi n t s :
· Number (and percentage) of patient s  in each arm with
microbiological eradication** of all ba s eline pathogen s  at the EO S
visit
**microbiological eradication of all ba s eline pathogen s  i s  defined
as an end of s tudy quantitative urine culture that s how s  all
uropathogen s  found at ba s eline are reduced to <10 5 C F U/mL and
all ba s eline pathogen s  are not detected by [CONTACT_132344] S  urine P CR (Cq>33 )
·S ubjective mea s urement of Treating Inve s tigator S ati s faction S co r e
as evaluated by [CONTACT_132345] s tionnaire at EO S
· Turnaround Time (a s  mea s ured in hour s ) of molecular diagno s tic
procedure s  compared to conventional diagno s tic s  (time from
collection of s ample s  to complete identification of organi s m( s ) and
availability of antimicrobial s u s ceptibility re s ult s )
· Overall a g reeability between the diagno s tic re s ult s  generated by
[CONTACT_132346] s u s  C& S  a s  a ss e ss ed by [INVESTIGATOR_121732] s cordant analy s i s
Safety:
Asse ss ment s  of s afety will include the following:
· Clinical ob s ervation s
· Vital s ign mea s urement s
· Laboratory te s t s
· Reported adver s e event s
· A ss e ss ment of Treatment Emergent Adver s e Event s  (TEAE) at
EOS
Stud y Arm s Active Comp ar ato r  A:  Diagno s i s  by M olecular Te s ting - Treatment
based on the re s ult s  of Urine P CR te s ting – even number s  on
randomization table.
·KingFi s her Duo P rime
·Quant S tudio 6 and 7 F lex Real-Time P CR S y s tem
·Quant S tudio 12k F lex Real-Time P CR S y s tem
Stati s tical
Meth o d ol o gy
UPH-STD-05-01
Vers i on:  [ADDRESS_149555] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHActive Compa r ato r  B:  Diagno s i s  by [CONTACT_132347] s ting - Treatment
based on the re s ult s  of Urine C & S  te s ting – odd number s  on
randomization table
Table s , li s ting s  and figure s  (TL Fs ) will be utilized to s ummarize data
associated with endpoint s ; di s cu ss ion s ection s  will be ba s ed on
Page 11 o f  44
Page 11 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
observation s  of thi s  s ummarized data, with reference to exi s ting
literature where appropriate.
2.2. Sc h e du le of A ss e ss me n t s
The s chedule of a ss e ss ment s  table provide s  an overview of the protocol vi s it s  and procedures.
The inve s tigator may s chedule vi s it s  (un s cheduled vi s it s ) in addition to tho s e li s ted on the
schedule of a ss e ss ment s , in order to conduct evaluation s  or a ss e ss ment s  required to protect the
well-being of the s ubject.
Table 1. Sc h e du le of A ss e ss me n t s
Assessments
Informed Consent
Eligibility Criteria
Demographics a
Medical history
Vital signs b
Physical Examination
Concomitant therapy
Randomization
Urine sample
collection
Urine PCR
Urine C&S
cUTI treatment
Adverse events c
Study conclusionScreening and
Baseline
 V1
(Day 0)
 x
 x
 x
 x
 x
 x
 x
 x
 x
x
x
xTreatment i
V2
(Day 0 to 5)
x
x
xf
xEnd-of-Study
V3
(Day 28 ± 7)
x
x
x
x
x
x
xd
x
xUnscheduled
Visit i
 UV
x
x
x
x
xe
xe
x
x
x
i Treatment vi s it (Vi s it 2) and/or un s cheduled vi s it s  may be conducted virtually
a Demographic s  include s ex, age, date of birth
b Vital s ign s  include body temperature ( ⁰C), S B P  (mmHg), DB P  (mmHg), HR (bpm) and may be
conducted by [CONTACT_132342] s tigator at their d i s cretion
c AEs  will be collected from the time of informed con s ent to EO S . Any ongoing AE s  at EO S  will
be followed until re s olution or s tabilization
d cUTI treatment may continue at EOS and after patient ’ s  s tudy exit
e Additional urine te s ting ( P CR, C& S , or both) may be ordered at un s cheduled vi s it s  at treating
Inves tigator’ s  di s cretion
f cUTI treatment mu s t initiate within 24 hour s  of receiving the te s t re s ult s  (either P CR or C& S  as
per s ubject’ s  a ss igned arm)
UPH-STD-05-01
Vers i on:  [ADDRESS_149556] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 12 o f  44
Page 12 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
3. BA C KGROUND AND RATIONALE
Urinary Tract Infection s  (UTI s ) are among the mo s t common rea s on s  for a patient to vi s it a
clinic, and are the s econd mo s t common type of bacterial infection in adult s . 1 Up to 33% of all
women experience a UTI in their lifetime. The majority of UTI s  are cau s ed by a s cen s ion of
uropathogen s  from the urethra to the bladder. The mo s t common pathogen cau s ing UTI i s
Esche r ichia coli , followed by [CONTACT_132348] s  s ap r ophyticu s , Ente r ococcu s , Kleb s iella, P r oteus
spp, p s eudomona s , Ente r obacte r , and yea s t. 2 However, a broader range of microorgani s m s  may
be re s pon s ible for UTI s  and the po ss i b ility of polymicrobial infection s  (co-infection or s upe r-
infection) f r equently complicate the clinical pi[INVESTIGATOR_1103] s  of UTI.
The mo s t common UTI, in a s etting o f  functionally and s tructurally normal urinary tract, i s
uncomplicated acute cy s titi s . UTI i s  cla ss ified according to the anatomical s ite of infection, and
distingui s he s  between lower tract infection s  of bladder (cy s titi s ), urethra (urethriti s ) and uppe r
tract infection s  of ureter, collecting s ystem, and renal parenchyma (pyelonephriti s ). 3 P atients
with ri s k factor s  are mo s t likely to experience complicated and/or recurrent UTI that are often
refractory to s tandard therapy and difficult to manage. Complicated UTI s  (cUTI s ) are frequently
accompanied by [CONTACT_132349] s y s temic s ign s  and s ymptom s , including fever, chill s , rigor, malaise,
back pain, f lank pain, and/or co s tovertebral angle (CVA) tenderne ss , in addition to common
urinary s ymptom s  s uch a s  urgency, frequency, dy s uria and/or hematuria. Condition s  that
increa s e the ri s k of cUTI include s tructural and/or functional abnormality of urinary tract,
immuno s uppre ss ion, underlying meta b olic di s ea s e, pregnancy, indwelling urinary catheter,
azotemia cau s ed by [CONTACT_132350] s ea s e, etc.
UTI treatment and management affect s  healthcare co s t s  and con s ume s  va s t re s ource s  in bot h
ambulatory and inpatient s etting s . Out p atient management for UTI s  i s  becoming limited due to
the ri s ing number of antimicrobial re s i s tant ca s e s . 4-[ADDRESS_149557] (functionally or anatomically), cUTI i s  a ss ociated with increa s ed ri s k o f
recurrent in f ection. F urthermore, the management of cUTI s tart s  with the u s e of empi[INVESTIGATOR_132327] -
spectrum a n timicrobial therapy that s ufficiently cover s  the mo s t commonly i s olated
uropathogen s . In clinical practice, the choice of antibiotic s  i s  determined ba s ed on urine cultu r e
and antimicrobial s en s itivity re s ult s . However, urine culture and s en s itivity i s  a time-con s uming
procedure, w here the turnaround time of the re s ult s  i s  at lea s t [ADDRESS_149558]- s pectrum antimicrobial agent s . An increa s ed antimicrobial re s istance
in uropathogen s  underlying cUTI i s  attributed to an increa s ed ri s k of recurrent infection, relapse,
and expo s ure to multiple cour s e s  of antimicrobial s , which can further complicate treatment
cours e, prolong ho s pi[INVESTIGATOR_307] s tay s , and lea d  to high mortality rate s . 7 The u s e of molecular te s ting f o r
the diagno s i s  of UTI/cUTI, s uch a s  polymera s e chain reaction ( P CR), can facilitate the detection
UPH-STD-05-01
Vers i on:  [ADDRESS_149559] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 13 o f  44
Page 13 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
of urinary pathogen s  with increa s ed s en s itivity and rapid turnaround time s  – that i s  typi[INVESTIGATOR_132328] 24 hour s  – and will enable the targeted admini s tration of antimicrobial agent s .
The propo s ed comparator P CR te s t has completed performance and clinical validation te s t s
where it identified 15 bacterial genu s  and s pecie s , 4 fungal s pecie s , 5 S TI-cau s ing
microorgani s m s , and 16 different cla s se s  of re s i s tance gene s . The s tudy reported that all po s itive
sample s  we r e identified via P CR at a r ate of >90%, indicating that P CR may be more accurate,
specific, and s en s itive than culture. The clinical utilization of P CR-ba s ed diagno s i s  of UTI/cUT I
would be extremely beneficial in en s u r ing timely treatment by [CONTACT_132351] s m s  and re s i s tance, and eliminating empi[INVESTIGATOR_132329], ultimately reducing UTI-related morbiditie s  and co s t s  in a high-ri s k patient
population.
The purpo s e of thi s  s tudy i s  to a ss e ss  clinical utility of molecular te s ting in the detection of
pathogen s  in cUTI s , identification of antimicrobial s u s ceptibility information, and
implementation of more efficaciou s  management of cUTI s .
4. ST U DY OBJECT I VE S  AND ENDPO I NT S
This inve s tigation intend s  to verify the clinical utility of urine P CR te s ting by [CONTACT_132352] s tic and therapeutic value s  of molecular diagno s tic method s  to traditional urine C& S  in
manageme n t of cUTI in adult s .
Table 2. S tu d y O b jective s  a nd  E ndp oi n t s
OBJECTIVE S ENDPO I NT S
Primary
· To evaluate patient s '
symptomatic re s pon s e s
followi n g diagno s i s  and
treatment ba s ed on the re s ult s
of the molecular method s
versu s  the tho s e of
conventional urine culture
method· Number (and percentage) of patient s  in each s tudy a r m
with favorable clinical outcome* at the EO S  vi s it
*favorable clinical outcome s  are defined a s  a clinical
respon s e of improvement a and/or cure b
a Clinical improvement i s  defined a s  1) Re s olution of
cUTI s ign s  and s ymptom s  pre s ent at ba s eline, 2)
Development of no new cUTI s ymptom s  and/or 3)
Avoidance of parenteral antibiotic therapy, in or o u t o f
hospi[INVESTIGATOR_307], at any time after randomization
b Clinical cure i s  re s olution of all acute s ign s  and
symptom s  of cUTI and improvement to s uch an extent
that no further antimicrobial therapy (IV or oral) i s
required for the treatment of the cUTI
UPH-STD-05-01
Vers i on:  [ADDRESS_149560] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 14 o f  44
Page 14 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
Secondary
· To dete r mine the efficacy of
antibiotic s election u s ing
molecular method s  ver s u s  the
conventional urine culture
method
· To a ss es s  clinical utility of
PCR result s  during the
clinical - deci s ion-making
phase in patient care
· To com p are the availability of
the antimicrobial
susceptibility information
from molecular te s ting and
conventional te s ting at the
time of initial antimicrobial
therapy
· To qua n tify the overall
agreeability between the
diagno s tic re s ult s  generated
by [CONTACT_132346] s u s  C& S· Number (and percentage) of patient s  in each arm with
microbiological eradication** of all ba s eline patho g ens
at the EO S  vi s it
**microbiological eradication of all ba s eline pathogens
is defined a s  an end of s tudy quantitative urine cultu r e
that s how s  all uropathogen s  found at ba s eline are
reduced to <10 5 C F U/mL and all ba s eline pathoge n s
are not detected by [CONTACT_132344] S  urine P CR (Cq>33)
·S ubjective mea s urement of Treating Inve s tigator
Satis faction S core a s  evaluated by [CONTACT_132345] s tionnaire at
EOS
· Turnaround Time (a s  mea s ured in hour s ) of molecula r
diagno s tic procedure s  compared to conventional
diagno s tic s  (time from collection of s ample s  to
complete identification of organi s m( s ) and availability
of antimicrobial s u s ceptibility re s ult s ) Overall
agreeability between the diagno s tic re s ult s  generated by
[CONTACT_132346] s u s  C& S  a s  a ss e ss ed by [INVESTIGATOR_121732] s cordant analy s i s
Safety will be a ss e ss ed ba s ed on clinical ob s ervation s , vital s ign mea s urement s , and releva n t
laboratory te s t s  at applicable s tudy timepoint s . TEAE will be a ss e ss ed at EO S . P articipant
reported ad v er s e event s  will be collected throughout the s tudy duration.
5. ST U DY DE SI GN
5.1. General De s ig n
This i s  a multi-center, randomized, pa r allel-a ss ignment, open-label, clinical utility s tudy to
evaluate urine P CR cUTI te s ting by [CONTACT_132353] s tic and therapeutic outcome s  of
molecular diagno s tic method s  to tho s e of traditional urine C& S  in management of cUTI in
adult s . At lea s t s ix (6) s ite s  will participate in thi s  s tudy. Approximately 120 eligible voluntee r s
will be enrolled per s ite. The s tudy i s  de s igned to be a 28-day s tudy, which include s  s ample
collection, sample te s t, treatment, and follow-up. P atient s  who meet all of the inclu s ion crite r ia
and none of the exclu s ion criteria and s ign an informed con s ent form will be enrolled in the
study. During the vi s it, each enrolled patient will provide a urine s ample (at lea s t 8 mL) at V 1
and V3; The collected urine s pecimens will be analyzed u s ing both P CR and C& S  method s  at
UPH-STD-05-01
Vers i on:  [ADDRESS_149561] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 15 o f  44
Page 15 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
each timepoint. Upon eligibility confi r mation by [CONTACT_132354] s tigator( s ), patient s  will be
randomized in a 1:1 ratio a s  follow s :
·     Diagno s i s  and treatment ba s ed on the re s ult s  of the urine P CR
·     Diagno s i s  and treatment ba s ed on the re s ult s  of the urine C& S
Table 1. S chedule of A ss e ss ment s  s ummarize s  the s tudy procedure s  to be performed at each
study vi s it. Individual s tudy procedure s  are de s cribed in detail below ( s ee s ection 8). It may be
required to perform outlined procedure s  at un s cheduled time point s , if deemed clinically
necess ary by [CONTACT_132342] s tigator( s ). Additional evaluation/te s ting may be deemed nece ss ary by [CONTACT_132355] r ( s ) for rea s on s  related to s ubject s afety.
5.2. Sc h ematic of S t ud y De s ig n
Note: SOC t r eatment will be dete r mined ba s ed on the diagno s tic evidence s  and the t r eating
Inves tigato r ’ s  judgement
UPH-STD-05-01
Vers i on:  [ADDRESS_149562] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 16 o f  44
Page 16 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
5.3. E s timate d  S t ud y D u ratio n
5.3.1. Stu d y D u ratio n  for Sub ject s
The duration of s tudy participation for each enrolled s ubject i s  approximately [ADDRESS_149563] complete s  the la s t s tudy-related vi s it/contact,
withdrawal from the s tudy, or i s  lo s t to follow-up. The la s t s ubject enrollment will occur when an
adequate n u mber of s ubject s  that s ati sf y the s tudy endpoint criteria are achieved.
5.4. I nterim A n aly s i s
No interim analy s i s  i s  planned in thi s  study.
6. SUBJECT S ELECT I ON AND W I THDRAWAL
6.1. I ncl us io n  Criteria
Subject s  m us t meet all of the following c r ite r ia to be con s ide r ed eligible fo r  admi ss ion to the
study:
I1. At lea s t 18 year s  of age at the time of con s ent;
I2. Presenting at lea s t two of the following new, per s i s tent or wor s ening cUTI s ign s  and
symp tom s  at s creening vi s it:
a) fever (temperature >38 degree s  Cel s iu s  or >100.4 degree s  F ahrenheit), hypothermia
(temperature <35.5 degree s  Cel s iu s  or <95.9 degree s  F ahrenheit), rigor s , or chill s
b) dy s uria, urinary frequency, urgency, or hematuria
c) suprapubic pain or pelvic pain
d) co s tovertebral angle (CVA) tenderne ss
e) nau s ea or vomiting
f) radiographic evidence of pyelonephriti s
g) leukocyto s i s
I3. Uri n e s pecimen with evidence of pyuria
a) dip s tick analy s i s  po s itive for nitrite and/or leukocyte e s tera s e, or;
b) ≥10 white blood cell s  (WBC s ) per cubic millimeter [mm3], or;
c) ≥10 WBC s  per high power field (hpf), or;
d) clinically s u s pected pyuria (e.g. change in urine color, s ediment in urine, or foul-
smelling urine)
UPH-STD-05-01
Vers i on:  [ADDRESS_149564] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 17 o f  44
Page 17 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
I4. Having cUTI that require s  microbiological diagno s i s  and treatment a s  s u s pected by [CONTACT_132356];
I5. Presenting active UTI that failed to re s olve on fir s t-line therapy or identified a s  a high -
risk*  patient population;
*Hig h -ri s k patient population include tho s e who are elderly ( ≥65year s ), male, pregnant,
having recurrent UTI ( ≥3/year), with underlying co-morbiditie s  (e.g. diabete s ,
immuno s uppre ss ion, or CKD), or with known functional and anatomical abnormalities o f
the u rinary tract (e.g. s tone s , s tent s , recent in s trumentation, indwelling catheter s ,
neurogenic bladder, or P KD)
I6. Able to provide at lea s t 8 mL u rine at vi s it 1 and 3;
I7. Willing to ab s tain from s exual intercour s e or u s e condom s  during any s exual contact [CONTACT_132357] S  vi s it i s  complete;
I8. Willing to comply with protocol requirement s , including availability for follow-up fo r  the
duration of the s tudy.
6.2. Excl us io n  Criteria
Subject s  meeting any of the following c r ite r ia will not be eligible fo r  admi ss ion to the s tudy:
E1. Unable or unwilling to provide written informed con s ent;
E2. Unable to read and write in Engli s h ( s urvey s  are not available or validated in any othe r
language than Engli s h);
E3. Cur r ently participating in, or ha s  participated in an interventional clinical trial with an
inves tigational product or device within 30 day s  prior to the S creening Vi s it;
E4. Cur r ently on or chronic u s e of any antibiotic s  for any clinical indication, other than U T I
(refer to s ection 6.3.);
E5. Receipt of any do s e of a potentially therapeutic oral or s y s temic antibiotic s  for the
treatment of UTI within 48 hour s  before the s tudy ba s eline urine i s  obtained
E6. Pregnant women with known f etal congenital anomaly (e.g., genetic abnormality or
majo r congenital malformatio n ) ba s ed on antenatal ultra s ound;
E7. Any rapi[INVESTIGATOR_132326] s ea s e or immediately life-threatening illne ss , including acute
hepatic failure, or re s pi[INVESTIGATOR_1399];
E8. M edical condition or other factor that in the judgment of the inve s tigator might affect
ability to comply with procedure s .
6.3. Pro h i b ite d  Prior or Co n comita n t T h era p y
At screening, the Inve s tigator or delegate will review prior medication s  u s e and record all p r io r
medication taken by [CONTACT_941] s ubject withi n  7 day s  before the s creening (or within 14 day s  before the
screening for all antimicrobial agent s , and within 30 day s  before the s creening for any othe r
inves tigational treatment).
UPH-STD-05-01
Vers i on:  [ADDRESS_149565] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 18 o f  44
Page 18 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
Patient s  with current or chronic u s e (a s  defined a s  medication taken daily for ≥30 day s  or u s ed
on an “a s  needed” ba s i s  for ≥6 month s ) of any antibiotic s  for any clinical indication s , other than
UTI, will be excluded from the s tudy. P atient s  will be excluded from the s tudy if they have
received any do s e of a potentially therapeutic oral or s y s temic antibiotic s  for the treatment o f
UTI within [ADDRESS_149566] Wit hd rawal from S t ud y
Removal b y  Inve s tigator:
The removal of a s tudy patient by [CONTACT_941] I nve s tigator will be ba s ed on the Clinical and P rotocol
Violation condition s  outlined below. Criteria for patient removal at the Inve s tigator’ s  di s cretion
are:
Clinical
A patient may be withdrawn from the s tudy if, in the opi[INVESTIGATOR_132330] s tigator, it is not
in the be s t intere s t of the patient to continue. P atient s  who experience an adver s e event
(AE)  or s evere adver s e event (SAE) will be a ss e ss ed by [CONTACT_132342] s tigator to determine
dispo s ition.
Protocol Violation
Protocol violation s  will be a ss e ss ed by [CONTACT_132342] s tigator on a ca s e-by-ca s e ba s i s  to
determine s ubject di s po s ition.
Patients can be withdrawn from the s tudy by [CONTACT_132342] s tigator at any time, or upon request
from the S pon s or and with mutual agreement between s pon s or and Inve s tigator. The
Inves tigator and/or delegate mu s t inform the patient and/or S pon s or of the removal and
provide a rationale.
7. ST U DY TREATMENT S
7.1. Subject E n rollme n t
Each s ite will recruit and s creen approximately 168 adult s  to identify the defined s tudy population
(n=120) ba s ed on an a ss umed 40% s c r een failure rate.
Patient s  will have their eligibility a ss es s ed by [CONTACT_132342] s tigator and/or delegate, through the review
of relevant medical hi s tory and other a ss e ss ment s  a s  defined in the protocol.
7.2. Te s ti n g S ite S etti n g
The te s ting s ite s  s hall be high-complexity te s ting laboratorie s  within clinical practice s .
UPH-STD-05-01
Vers i on:  [ADDRESS_149567] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 19 o f  44
Page 19 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
7.3. Stu d y Arm s
Active Comparator A
Diagno s i s  by M olecular Te s ting, and Treatment ba s ed on the re s ult s  of Urine P CR te s ting –
EVEN number s  on randomization table.
Active Comparator B
Diagno s i s  by [CONTACT_132347] s ting, and Treatment ba s ed on re s ult s  of the Urine C & S  te s ting –
ODD number s  on randomization table.
7.4. Ran d omizatio n
Enrolled patient s  will be randomized for one of two te s ting procedure s  u s ed to guide treatment.
Upon eligibility confirmation, patients will be a ss igned a unique s equential
enrollment/ r andomization number. P atient s  with an odd enrollment number will receive
treatment guided by [CONTACT_113524] C& S  re s ults, and patient s  with an even enrollment number will receive
treatment guided by [CONTACT_113524] P CR re s ult s .
Enrollment number s  will only be u s ed once. If a patient withdraw s  from participation in the
study, then their enrollment number cannot be reu s ed. Enrollment number s  will be a ss igned
strictly s equentially a s  potential patient s  become eligible for randomization.
7.5. Bli nd i n g a nd  U nb li nd i n g
The treating Inve s tigator will only ha v e acce ss  to the re s ult s  of their patient s ’ a ss igned te s t, and
will be blinded to the re s ult of the comparator te s t until after the end of the s tudy.
The treating Inve s tigator s hall gain an acce ss  to the re s ult of comparator te s t in following cases:
·If a patient ’ s  a ss igned te s t re s ult come s  back negative UTI.
·If a patient i s  withdrawn from the s tudy. In the opi[INVESTIGATOR_132330] s tigator, it i s  not i n  the
best intere s t of the patient to continue s tudy therapy and/or lack of efficacy.
·If patient decide to di s continue s tudy participation.
8. ST U DY V ISI T S
8.1. Pre -s cree n i n g
Recruitment will commence once the clinical s ite ha s  received approval from the IRB, and s ta ff
have been d elegated to perform recruitment activitie s . P atient s  may s elf-pre s ent by [CONTACT_132358] a s  per the IRB-approved recruitment material s  to complete the pre- s creenin g
procedure, at which point they will be s cheduled for a s creening and ba s eline vi s it. Any
UPH-STD-05-01
Vers i on:  [ADDRESS_149568] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 20 o f  44
Page 20 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
recruitment material s  u s ed will be app r oved by [CONTACT_132359] s  prior to di s tribution
and/or u s e.
8.2. Vi s it 1 - S cree n i n g a nd  Ba s eli n e (Day 0)
The delegated s tudy s taff will explain the s tudy objective s , the proce ss , and the modalitie s  o f
participation in the re s earch. The s tud y  s taff will an s wer any que s tion s  the patient may have.
Patient s  will then be given ample time to review the Informed Con s ent F orm (IC F ) and, a s k any
question s  before s igning the appropriate s ection( s ). The IC F  will then be s igned by [CONTACT_132355] r  or delegate. A copy of the Informed Con s ent F orm (IC F ) will be provided to the
patient for their record s . The informed con s ent proce ss  will be documented in the s ource
document s .
Once the IC F  i s  s igned by [CONTACT_132360] s ted to by [CONTACT_132342] s tigator s  or delegate, the s tudy
staff will c o llect demographic information, vital s ign s  and relevant medical hi s tory, and conduct
an examination in order to verify the eligibility criteria (excluding urine analy s i s  re s ult s ).
If the patient s  meet the inclu s ion crite r ia and none of the exclu s ion criteria (excluding urine
analy s i s  re su lt s ), urine s pecimen s  will be collected u s ing acceptable method s  (refer to s ecti o n
9.1). The collected urine s pecimen s  will be analyzed by [CONTACT_132361] P CR and C& S  in accordance
with S OP s .
Prior to Vi s it 2 and upon confirmation of eligibility by [CONTACT_132362] s tigator, patient s  will be enrolled
into the s tu d y and will be randomized into one of two s tudy arm s  ( P CR-arm or C& S -arm).
8.3. Vi s it 2 - Treatme n t (Day 0 + 5 )
Visit [ADDRESS_149569]  initiate within 24 hours of the te s t re s ult (urine C& S  or urine P CR a s  applicable to
subject’ s  a s signed arm) becoming available and within s pecified buffer window. S tudy s taff will
record the data a ss ociated with the P CR te s t report or C& S  te s t report in a dedicated eCR F ,
including time of the te s t report s .
Visit 2 may be conducted virtually, a s  per treating Inve s tigator’ s  di s cretion, if the patient ca r e
can be continued in an out-patient clinic/ s etting.
The identit y  of the patient will be con f irmed by [CONTACT_132363]. The
Inves tigator or delegate will review medical hi s tory. P atient s  will be a s ked about any changes in
their health, and any concomitant treatment s  admini s tered s ince the la s t vi s it.
UPH-STD-05-01
Vers i on:  [ADDRESS_149570] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 21 o f  44
Page 21 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
The treating Inve s tigator will utilize t h e re s ult s  of the patient s ’ randomly a ss igned s tudy arm f o r
their clinical deci s ion making and patient care. The treating Inve s tigator MU S T NOT*  review
the re s ult s  of the (una ss igned) comparator te s t before treatment.
*Exception :  If the patient ’ s  a ss igned te s t detect s  no U T I, the t r eating Inve s tigato r  will r eview the
result of the compa r ato r  te s t. In the c as e of conco r dant r e s ult between two compa r ato rs  (both
negative), the patient will be r efe rr ed to SOC and excluded f r om the s tudy. In the ca s e of
disco r dant r e s ult, the patient will be r efe rr ed to SOC and the r e s ult of patient ca r e will be
followed u p  by [CONTACT_132342] s tigato r  o r  delegate. T he patient data will be collected and u s ed fo r
disco r dant analy s i s  a s  planned ( r efe r  to s ection 11.3.4).
The treatin g  Inve s tigator s hall provide continuou s  patient care a s  per their medical deci s ion(s ) .
Thes e include, but are not limited to: r eque s t of un s cheduled vi s it s , admi ss ion/referral of patient
to receive in-patient care, admini s trati o n of IV or oral antibiotic s , in/out-patient care, or u s e o f
broad- s pectrum antibiotic s .
8.4. Vi s it 3 - E nd -of- S t ud y (Day 28 ± 7)
EOS a ss e ss ment s hould be performed in-per s on within the s pecified buffer period.
The Inve s tigator or delegate will perf o rm/collect the following:
·Vital s ign s
·Phy s ical examination (may be complete, targeted, or omitted; di s cretion of the
Inves tigator)
·Rec o rd( s ) of any adjunctive therapeutic procedure s  performed
·Rec o rd( s ) of concomitant medication s
·A ss e ss ment of clinical outcome( s )
·Rec o rd( s ) of any AE s / S AE s
Urine s pecimen s  will be collected for microbiological evaluation. In ca s e the re s ult of urine
specimen identifie s  an un s ucce ss ful treatment, the patient may be followed-up to verify the f inal
clinical outcome if deemed nece ss ary by [CONTACT_132364] s tigator.
When both the re s ult s  of urine C& S  and urine P CR become available, the treating Inve s tigato r
will an s wer an evaluation que s tionnaire concerning hi s /her judgement of the diagno s tic te s t and
therapeutic value of urine P CR and urine C& S .
In ca s e of clinical failure* a s  determined by [CONTACT_132354] s tigator at EO S , the patient ’ s  condition
will be considered an AE and followe d -up accordingly.
*Clinical failure i s  defined a s  a patient who ha s  1) on-going AE/ S AE at EO S  and/or 2) per s istent
cUTI s ymptom s  and/or 3) developed new s ymptom s  of cUTI.
UPH-STD-05-01
Vers i on:  [ADDRESS_149571] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 22 o f  44
Page 22 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
At the end o f the s tudy, the Inve s tigator will complete the S tudy Exit F orm pre s ent at the end o f
the eCRF p o rtfolio. Thi s  form mu s t al s o be completed in the event of premature termination o f
the patient's participation s hould they, the Inve s tigator, or the S pon s or choo s e to di s continue
their partici p ation.
9. AS S E SS MENT S  AND PRO C EDURE S
9.1. Uri n e S am p le A n aly s i s
Urine s ample s  (at lea s t 8 mL) will be collected from a clean-catch mid- s tream urine s pecimen at
V1and V3. P atient s  will be in s tructed to follow the clean catch in s truction s  provided at the
collection s ite. The Inve s tigator or delegate may collect the urine s ample s  u s ing a properly
disinfected collection technique s  s uch a s  through a newly-placed urinary catheter, cy s to s copy, o r
suprapubic a s pi[INVESTIGATOR_1516], a s  per clinical indication ( S ee Appendix II for further procedural
guidance). A dditional urine s ample collection and analy s i s  may be conducted at an un s cheduled
visit, if deemed nece ss ary by [CONTACT_132354] s tigator. S pecimen s  mu s t be immediately refrigerated
upon collection and s ubmitted to the central laboratory within [ADDRESS_149572] ID, DOB, vi s it number, s tudy ID, method o f
collection, date and time of collection. The collected s ample will be placed in a s mall bag along
with the te s t requi s ition form. The proce ss ing laboratory will aliquot the s ample upon recei p t,
one to be a n alyzed by P CR (maximum 3mL) and the other to be analyzed by C& S  (minimum
5mL). The sample will be s tored unde r  the appropriate temperature condition s  until analy s is o f
the sample.
Urine C&S
All urine s ample s  for Urine C& S  will be s hipped to the central laboratory. Urine culture,
isolation of uropathogen( s ), initial ide n tification of pathogen( s ) and bacterial count s  in urine will
be conducted in the central laboratory.
Urine s ample s  will be cultured and quantified u s ing a calibrated loop to identify a quantitative
count of bacteria at a lower limit of 1 0 5 C F U/mL. All purified pathogen( s ) will be further
analyzed fo r  s pecie s  identification an d  antimicrobial s u s ceptibility. The analy s i s  re s ult s  will be
recorded in the s ource document and eCR F .
Urine PCR
Urine s ample s  will be analyzed u s ing the li s ted molecular te s ting device s :
· King F i s her Duo P rime
UPH-STD-05-01
Vers i on:  [ADDRESS_149573] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 23 o f  44
Page 23 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
· Qua n t S tudio 6 and 7 F lex Real - Time P CR S y s tem
· Qua n t S tudio 12k F lex Real-Time P CR S y s tem
Bacterial a n d fungal pathogen-directed qualitative P CR amplification of target region of
24 uropathogen s , and 16 different cla s se s  of re s i s tance gene s  ( s ee Appendix III. Device
specificatio n : pathogen target s  and Cq range s , antibiotic s  re s i s tance gene s  and Cq range s ).
Further detail s  of the s tandardized S O P  for P CR procedure will be di s tributed from a central
laboratory to all laboratory s ite s  prior to the commencement of the s tudy.
9.2. Body Tem p erat u re
Body temperature will be mea s ured at Vi s it 1, Vi s it 3, and po ss ibly at un s cheduled vi s it s .
Temperature s hould be mea s ured orally, rectally, or by [CONTACT_132365]. Temperature s hould be
assess ed a s  per in s titution guideline s  while at the s tudy s ite, and recorded in the eCR F .
9.3. Bloo d  Pre ssu re a nd  Heart Rate
Blood P re s sure and Heart Rate will be mea s ured at Vi s it 1, Vi s it 3, and po ss ibly at un s cheduled
visits . Blood P re ss ure and Heart Rate will be mea s ured according to the s ite’ s  S O Ps . Additional
Blood P re ss ure and Heart Rate collection s  or change s  to collection time s  will be permitted, as
necess ary, at the di s cretion of the Inve s tigator to en s ure proper collection of s afety data.
Appropriately s ized and calibrated equipment will be u s ed at each mea s urement of Blood
Press ure an d  Heart Rate.
9.4. Physical Exami n atio n
The Inve s tigator or delegate will perform a phy s ical examination at V1 and V3. The phy s ical
examination may be complete, targete d , or omitted at the Inve s tigator’ s  di s cretion, ba s ed on the
patient’ s  condition and circum s tance s .
9.5. Termi n atio n  of t h e S t ud y
The s tudy may be terminated at any time by [CONTACT_941] S pon s or, P I, or applicable regulatory autho r ity
(IRB). If the s tudy i s  terminated prematurely, the P I/Inve s tigator( s ), patient s , and the regulato r y
authoritie s  mu s t all be notified of the termination promptly. Upon termination of the s tudy
whether premature, or due to completi o n, s ite clo s e-out activitie s  will be initiated including
regulatory clo s e-out to the appropriate authoritie s .
10. SAFETY I N S TRUCT I ON S  AND GU I DANCE
UPH-STD-05-01
Vers i on:  [ADDRESS_149574] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 24 o f  44
Page 24 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
10.1. Defi n itio ns  of A d ver s e Eve n t s  (AE s )
10.1.1. Adver s e Eve n t
Definition:  An adver s e event can be any unfavorable and unintended s ign, s ymptom, or
disea s e that happen s  during the s t u dy participation (defined a s  after the time of initial
informed con s ent), whether or not it i s  con s idered s tudy drug, device, or procedure-related.
Adver s e event (AE) may be mild, moderate, or s evere, and may be cau s ed by s omething
other than the drug or therapy being given. A pre-exi s ting condition i s  one that i s  pre s ent at
study entry and i s  reported a s  part of the s ubject’ s  medical hi s tory; if the frequency, intensity,
or character of the condition wor s en s  during the s tudy participation, it s hould be reporte d  as
an AE. A ny abnormality that pre s ent s  during a medical te s t i s  to be defined a s  an AE if it
produce s  clinical s ign s  and/or s ymptom s , require s  intervention, or deemed clinically
significant by [CONTACT_132366] s tigator. S u b ject s hould be in s tructed to report all AE s  to the
inves tigator s  or s tudy s taff. Adver s e event s  mu s t be followed-up to re s olution or when the
condition i s  deemed s table by [CONTACT_132342] s tigator.
10.1.2. Serio us  A d ver s e Eve n t
A Seriou s  Adver s e Event ( S AE) is any AE, regardle ss  of cau s ality that re s ult s  in any of the
following:
· Death;
· Life-threatening AE;
· Require s  inpatient ho s pi[INVESTIGATOR_059];
· Per s i s tent or s ignificant di s ability/incapacity or;
· M edical event that may jeopardize the patient/ s ubject and may require medical or
surgical intervention.
10.2. Collecti n g, Recor d i n g, a nd  R e p orti n g of AE s
10.2.1. Collecti n g a nd  Recor d i n g
The Inve s tigator or delegated s tud y  s taff mu s t record all adver s e event s  in an AE form w ith
information about:
· Detail s  of adver s e event
· Date of on s et (time can be recorded, if applicable)
· Inten s ity (mild, moderate, s evere)
· Cau s al relation s hip to s tudy in v olvement (probable, po ss ible, unlikely, not related)
· Other action s  taken
· Date and time of outcome
UPH-STD-05-01
Vers i on:  [ADDRESS_149575] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 25 o f  44
Page 25 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
· Outcome
All AE s , regardle ss  of cau s al relation s hip to s tudy involvement, s panning from the s ignatu r e
of the informed con s ent form until the end of the s tudy a s  defined by [CONTACT_132367], are to be recorded on the corre s ponding eCR F .
10.2.2. G u ideli n e s  for Re p orti n g A dv er s e Eve n t s
The following timeline s  apply to the reporting of AE s / S AE s  a s  applicable. The Inve s tigato r
must n o tify the S pon s or:
· Within 24 hour s  of the Inve s ti g ator becoming aware of the event if it re s ult s  in death o f  a
patient
· Within 2 week s  (10 bu s ine ss  day s ) after becoming aware of the event if:
o It i s  an AE which is related to the conduct of the s tudy;
o It i s  an AE that i s  e x pected (li s ted in the IC F  a s  a potential s ide effect) but is
occurring more frequently than expected;
o It i s  an unexpected A E/ S AE that i s  related to the conduct of the s tudy but is
not life-threatening
·Annually or upon s tudy completion (together with the S tudy S tatu s  Report) if:
o It i s  an expected AE (li s ted in the IC F  a s  a potential s ide effect);
o It i s  an unexpected A E that i s  unlikely to be related to the conduct of the study
and i s  not life-threatening.
During the cour s e of a clinical s tudy, the s pon s or s hall notify the IRB of any s u s pected
adver s e reaction to s tudy treatment that i s  both s eriou s  and unexpected:
·A s i n gle occurrence of a s eriou s , unexpected event that i s  uncommon and s trongly
associated with drug expo s ure;
·A s i n gle occurrence, or more often a s mall number of occurrence s , of a s eriou s ,
unexpected event that i s  not commonly a ss ociated with drug expo s ure, but uncommon in
the study population;
·M ultiple occurrence s  of an AE that, ba s ed on an aggregate analy s i s , i s  determined t o  be
an unanticipated problem;
·An A E that i s  de s cribed or add r e ss ed in the inve s tigator’ s  brochure, protocol, or inf or med
consent document s , but occur s  at a s pecificity or s everity that i s  incon s i s tent with p r io r
observation s ;
·A s eriou s  AE that i s  de s cribed or addre ss ed in the inve s tigator’ s  brochure, protocol, o r
infor med con s ent document s , but for which the rate of occurrence in the s tudy repre s ents
a clinically s ignificant increa s e in the expected rate of occurrence;
·Any other AE or s afety finding that would cau s e the s pon s or to modify the inve s tigato r’ s
brochure, s tudy protocol, or informed con s ent document s , or would prompt other action
by [CONTACT_132368] s ure the protection of human s ubject s .
UPH-STD-05-01
Vers i on:  [ADDRESS_149576] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 26 o f  44
Page 26 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
completion of the s tudy. The participa n t s  will be enrolled in at lea s t 6 s tudy s ite s  (with an equal
distribution of participant s  enrolled pe r  s ite).
Exact - Proportions: Inequality, two independent groups (Fisher's exact test)
Options: Exact distribution
Analysis: A priori: Compute required sample size
Input: Tail(s) = One
Proportion p1 = 0.7
Proportion p2 = 0.8
α err prob = 0.05
Power (1- β err prob) = 0.85
Allocation ratio N2/N1 = 1
Output: Sample size group 1 = 287
Sample size group 2 = 287
Total sample size = 574
Actual power                                 = 0.8513193
Actual α                                        = 0.0404397
11.2. Stu d y Po pu latio n
The Intention-to-Treat (ITT) population : All participant s  who participate in the s tudy and get
randomized into one of the s tudy’ s  arm, without any major protocol violation s  which would
significantly compromi s e the integrity of collected data.
The M odified Intent-To-Treat ( M od-ITT) P opulation : All participant s  from the ITT with a
positive P CR or C& S  re s ult s  after ran d omization a ss ignment.
11.3. Analy s i s  Pla n
11.3.1. Analy s i s  Po pu latio n
The M od-ITT P opulation will be u s ed for the analy s i s  of the primary and s econdary endpoints
(exception f or the di s cordance s tudy, where the ITT population will be u s ed for a ss e ss ing the
agreement b etween method s ).
11.3.2. Primary a nd  S eco nd ary E ndp oi n t s
The primary endpoint i s  the number (and percentage) of patient s  in each s tudy arm with F Cl
at the E OS  vi s it; thi s  term i s  defined a s  a clinical r e s pon s e of imp r ovement and/or clinical
cure:
Clinical r e s pon s e of imp r ovement i s  defined a s :
1) Re s olution of cUTI s ign s  and s ymptom s  pre s ent at ba s eline, and/or
UPH-STD-05-01
Vers i on:  [ADDRESS_149577] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 28 o f  44
Page 28 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
·Pregnancy: P regnant (po s itive for te s t) ver s u s  Non- P regnant (negative for te s t or not
applicable)
11.3.6. Dat a  A n aly s i s  of S eco nd ary E ndp oi n t s
Descriptive and trend s tati s tic s  will be performed for the s econdary variable s . Continuous
variable s  will be pre s ented with the average and s tandard deviation or median range, a s
appropriate, and categorical varia b le s  will be pre s ented a s  proportion s . An EDA will be
performed for the s econdary and exploratory variable s  (except s afety) to analyze and
inves tigate data s et s  and s ummarize their main characteri s tic s , employing data vi s ualization
method s  where applicable. Exploratory s ubgroup analy s i s  will be ba s ed on the potential
prognostic variable s , including but not limited to the s trata de s cribed in s ection 11.3.4. A ll
statis tical s ignificance te s t s  will be conducted with an alpha of 0.05, unle ss  s pecified
otherwi s e. If the underlying population i s  ob s erved to deviate s ignificantly from normality, a
non-parametric s tati s tical approach will be u s ed.
12. PROTOCOL DEV I AT I ON( S )
Protocol Deviation ( P D) form s  mu s t be filed for an unintended or planned (if any and if
approved i n  prior to occur) deviation f r om thi s  protocol. P D s  which place patient s  at increa s ed
risk of harm, or affect data integrity may be con s idered P rotocol Violation s  ( P V s ) and mu s t be
reported to the appropriate regulatory authoritie s  no later than 2 week s  (10 bu s ine ss  day s ) f r om
the time of identification. P D s  will be filed in the applicable patient chart, and in the Trial Maste r
File (T M F) upon s tudy clo s eout. P D s  will be filed and s igned by [CONTACT_132369] s tudy s taff and
reviewed and s igned by [CONTACT_132342] s tigat o r. The Inve s tigator will determine if the P D i s  reportable
to the IRB ba s ed on an a ss e ss ment of the patient ’ s  s afety and/or the effect s  on the integrity o f  the
study data.
13. PROTOCOL CHANGE S
Any change s  to the protocol mu s t be t r acked and documented in accordance with Good
Documentation P ractice s , applicable S O Ps , and regulatory over s ight. The rea s on s  for change
must be documented in writing and provided to the regulatory bodie s  and approval mu s t be
granted prior to implementation unle ss  s ubject s afety i s  at ri s k. All ver s ion s  of the protocol must
be included in the T MF . All protocol change s  will be documented in the s tudy report.
14. ETH I CAL CON SI DERAT I ON S
14.1. Ethical Co ndu ct of t h e S t udy
UPH-STD-05-01
Vers i on:  [ADDRESS_149578] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 31 o f  44
Page 31 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
The s tudy will be performed in accordance with ethical principle s  that are con s i s tent with t h e
ICH guideline s  for Good Clinical P ractice (IC F  GC P  E6(R2)), applicable regulatory
requirement s  and the S pon s or’ s  policy on Bioethic s .
14.2. I RB A pp roval
All nece ss ary form s , adverti s ement s , and s ubject-facing s tudy document s  will be compi[INVESTIGATOR_69015] a
submi ss ion to an In s titutional Review Board (IRB) for approval prior to the conduct of the study.
No conduct of the s tudy will commence until written approval ha s  been obtained from the IRB.
The S pon so r and/or CRO mu s t adhere to the requirement s  of the IRB and notify them of an y
study document change s , protocol amendment s , and reportable protocol deviation s /violations.
Study termination mu s t be reported to the IRB, and renewal of s tudy approval mu s t be obtained
annually (or a s  per IRB’ s  s tipulation s ).
14.3. I nforme d  Co ns e n t Form ( I CF)
Informed c o n s ent will be obtained from patient s  by [CONTACT_132369] s tudy s taff. The s taff will explain
the study and review each page of the con s ent document. P atient s  will then be given ample time
to review the Informed Con s ent F orm and a s k any que s tion s  before s igning the appropriate
section( s ). The Informed Con s ent F orm (IC F ) will contain pertinent s tudy detail s , a s tatement
indicating t h e patient i s  free to withdraw from the s tudy at any point and for any rea s on, co n tact
information of the IRB (to report ethical concern s ), local and applicable regulation s  s urrounding
disclo s ure of per s onal and health info r mation of the patient s , and a s ection explaining the
potential risk( s ) of participating in the s tudy. A copy of the informed con s ent document will be
given to the patient for their record s . The informed con s ent proce ss  will be documented in the
source document (including the date), and the form s igned, before the patient undergoe s  any
study- s peci f ic procedure s .
14.4. Ri s k s  a nd  Proce du re s  to Mi n imize Ri sk
Potential risk s  are di s clo s ed to the s tudy patient s  in the IC F  prior to their participation in the
study. The ri s k of the therapeutic intervention i s  judged comparable in compari s on to s tanda r d o f
medical care. The propo s ed inve s tigation s  and management s trategie s  are all part of routine
optimal care. The identifiable ri s k s  are a ss ociated with cUTI s . The s e ri s k s  include but are not
limited to:
·Allergic reaction to antimicro b ial therapy
·Pro g re ss ion or relap s e of cUTI
·Nau s ea, vomiting, headache, sk in ra s h, hyper s en s itivity reaction, anaphylaxi s  reaction
·Yeast infection (vaginiti s /vulvovaginal candidia s i s )
·Pro g re ss ion to acute renal failure
UPH-STD-05-01
Vers i on:  [ADDRESS_149579] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 32 o f  44
Page 32 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
·C. difficile infection
·Sep s i s
There may be unknown ri s k s .
While there i s  minimal potential ri s k of lo ss  of privacy and lo ss  of confidentiality, multiple
precaution s  will be in place to protect the s ubject’ s  privacy.
15. QU A L I TY A SS URANCE AND QUAL I TY CONTROL
15.1. Au d iti n g a nd  Insp ecti n g
The S pon so r, or de s ignee( s ), will monitor the s tudy to en s ure that the right s  and well-being o f  the
subject s  are protected, for compliance with the protocol, for compliance with applicable la w s and
regulation s . Quality a ss urance audit s  may be performed by [CONTACT_941] S pon s or or health authority
during the cour s e of the s tudy or after it s  completion.
The P I and s ite s  agree to comply with the S pon s or and regulatory requirement s  for auditing the
study. Thi s  include s  acce ss  to the s ource document s  for s ource data verification.
15.2. Stu d y Mo n itori n g
Prior to the s tart of the s tudy, the S pon s or repre s entative s , s ite per s onnel, and any third-party
vendor repre s entative s  will hold at least one meeting to go over the detail s  of the s tudy de s i g n
and plan s  for s tudy execution. The delegated s tudy monitor will conduct ri s k-ba s ed monitoring
to identify, a ss e ss , and mitigate the ri sks  that could affect the quality or s afety of a s tudy.
Monitoring and data verification may be performed remotely.
15.2.1. Re sp o ns i b ilitie s  of t h e In ve s tigator( s )
The Inve s tigator mu s t en s ure com p liance with all procedure s  required by [CONTACT_941] s tudy protocol
and with all s tudy procedure s  pro v ided by [CONTACT_941] S pon s or. The Inve s tigator agree s  to provide
accurate s tudy data reque s ted by t h e s tudy protocol (with the help of the CR F  or other
appropriate document s ). If any proce ss  include s  tran s fer of data, all protective mea s ure s
should be in place to protect and maintain patient confidentiality while data i s  being
trans ferred. The Inve s tigator may appoint other individual s  who may be deemed appropriate
as Sub-inve s tigator s  to a ss i s t in the conduct of the clinical s tudy. All s tudy s taff will be
delegated in a timely manner and li s ted in the T MF . The Inve s tigator will provide all s tudy
staff with a copy of the clinical s t u dy protocol, IC F , ancillary form s , and all nece ss ary details
prior to delegation.
UPH-STD-05-01
Vers i on:  [ADDRESS_149580] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 33 o f  44
Page 33 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
15.2.2. Re sp o ns i b ilitie s  of t h e Sp o nso r
The S p o n s or, or re s pon s ible CRO, of thi s  clinical s tudy i s  re s pon s ible for en s uring the p r ope r
conduct of the clinical s tudy with r egard s  to ethic s , clinical s tudy protocol compliance, and
integrity and validity of the data recorded on the CR Fs .
15.2.3. Source Doc u me n t Re qu ireme n t s
The monitoring team will check the CR F /eCR F  data again s t the s ource document s  to ve r i f y
accurate tran s fer of data, except fo r  tho s e entrie s  captured directly into the CR F /eCR F  as
stipulated in the Clinical Trial M onitoring P lan (CT MP ).
16. DATA HANDL I NG AND RECORD KEEP I NG
All U S -ba s ed s tudy s ite s  and laboratorie s  providing s upport for thi s  s tudy, mu s t, where
applicable, comply with the Health Insurance P ortability and Accountability Act of 1996
(HIPAA). A s ite that i s  not a Covered Entity a s  defined by [CONTACT_132370] P AA mu s t provide documentation
of thi s  fact to the CRO/ S pon s or.
An independent, third-party clinical trial management s y s tem (CT MS ) and/or Electronic Data
Capture (EDC) s oftware vendor may be u s ed at the s ite for laboratory report data and patie n t -
associated document s torage. All activitie s  and action s  performed on the vendor platform( s ) will
be tracked and will produce an electronic audit-trail in accordance with regulatory s tandard s .
Paper document s  will be u s ed in the e v ent that the CT MS  and/or EDC s y s tem( s ) i s  not u s ed due
to any unfo r e s een or incidental circum s tance cau s ing di s ruption to data collection. All paper
documentation will be s ubject to ICH - GC P  E6(R2) regulation s  and applicable guideline s .
The P I and/or delegated s tudy s taff ag r ee to maintain accurate CR Fs  and s ource documentation.
Source doc u ment s  are the original s  of any document s  that allow verification of the exi s tence o f
the patient and s ub s tantiate the integrity of the data collected during the s tudy.
The CRO a n d/or S pon s or will s upply the s ite with either paper or electronic CR Fs  for each
patient. CR Fs  will be completed only by [INVESTIGATOR_11826] s on s  delegated by [CONTACT_941] P I. Correction s  will be made
so as  not to obliterate original data an d  will be identified and dated by [CONTACT_132371] s on who made the
correction. The P I/delegate s  will allo w  de s ignated repre s entative s  and regulatory bodie s  to have
direct acce ss  to the s ource document s  to verify the data reported in the CR Fs .
UPH-STD-05-01
Vers i on:  [ADDRESS_149581] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 34 o f  44
Page 34 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
16.1. Confi d e n tiality
The P I and/or delegated s tudy s taff will en s ure that the confidentiality of the patient ’ s  data w ill
be pre s erved to the extent permitted by [CONTACT_2371]. All partie s  will en s ure protection of patient personal
data and will not include name s  or other identifiable patient data in any report s , except whe r e
required by [CONTACT_2371]. Document s  that hou s e patient information, s uch a s  s igned IC Fs  and per s onal
information/demographic form s  will b e maintained and s tored by [CONTACT_132369] s tudy s taff unde r
strict acce s s.
16.2. Source Data a nd  S o u rce Docume n t s
As defined by [CONTACT_132372] r ence on Harmonization (ICH), s ource data are defined as
all information in original record s  and certified copie s  of original record s  of clinical findin g s,
observation s , or other activitie s  in a clinical s tudy nece ss ary for the recon s truction and evaluation
of the s tudy.
All s ource data and s ource document s  will be s tored and archived according to local regulato r y
requirement s . F or thi s  s tudy, s ource data and document s  include, but are not limited to:
• S igned and dated Informed Con s ent F orm (IC F );
• Name, s ex, date of birth and other per s onal information/demographic information;
• S ubject ID;
• Date and time of each vi s it;
• All clinical mea s urement s  and laboratory re s ult s ;
• S tatu s  of patient throughout the s tudy;
• Any fir s t-hand s tudy-related data directly captured on paper and/or entered i n to
eCRFs  via tablet, computer or other electronic device s ;
• Li s t of concomitant medication;
• Adver s e event s  or cha n ge s  in health;
• Rea s on for di s continuation/withdrawal, if applicable.
16.3. Ca s e Re p ort Form s  (CRF s )
Case report form s  will be created following protocol finalization and approval to capture s tudy
data. The s e form s  may be in the form of paper, or may be electronic (eCR Fs ). An eCR F  s ystem,
provided by [CONTACT_120620]-party vendor, may be u s ed to capture data. P rior to deployment
of the s tudy, the eCR F  s y s tem will be v alidated and s pecified to addre ss  s ource documentation,
in accordance with S pon s or and regulatory requirement s .
16.4. Dat a  s torage a nd  Acce ss
UPH-STD-05-01
Vers i on:  [ADDRESS_149582] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 35 o f  44
Page 35 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
Data will be entered into the s ource document s , checked for di s crepancie s  and queried for any
issue s  in accordance with s ite-approved S O Ps . The s ite s  are re s pon s ible for collecting and
inputting data into the de s ignated s tudy databa s e, either directly or tran s cribing from s ource
document s . The databa s e hou s ing the eCR F  input will be ho s ted by [CONTACT_132373] F  vendor. All vendo r
data acce ss  and entry can only be performed by [CONTACT_113640] u s er s , u s ing a unique u s er login and
password. Login activity and data entry will be tracked in an automated audit trail. The S ponso r ,
site(s ) and CRO will permit s tudy-related monitoring, audit s , IRB review, and regulatory
inspection s,  providing direct acce ss  to s ource data/document s . P aper CR Fs  may al s o be
monitored f or completion, queried thr o ugh internal review by [CONTACT_132369] s tudy s taff, identified
items  re s olved and documented where applicable, and any required data from s ource documents
will be ente r ed into the final databa s e prior to locking.
16.5. Dat a  Q u ality A ssu ra n ce
Data cleaning will be performed to check for completene ss  and con s i s tency of data u s ing s ystem,
programmed, and manual edit check s . Di s crepancie s  in data will be re s olved through querying,
delegation and re s olution in accordance to s ite S O Ps .
UPH-STD-05-01
Vers i on:  [ADDRESS_149583] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 36 o f  44
Page 36 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
17. REFERENCE S
1. Szlachta- M cGinn A, Dougla ss  K M , Chung UYR, J ack s on N J , Nickel J C, Ackerma n  AL.
Molecular Diagno s tic M ethods Ver s u s  Conventional Urine Culture for Diagno s i s  and
Treatment of Urinary Tract Infection: A S y s tematic Review and M eta-analy s i s . Eur U r ol
Open S ci. 2022;44:113-124. P ubli s hed 2022 S ep 2. doi:10.1016/j.euro s .2022.08.[ADDRESS_149584] infection in urine s pecimen. P ak J  M ed S ci. 2020;36(3):391-395.
doi:10.[ZIP_CODE]/pjm s .36.3.[ADDRESS_149585] infecti o ns in
the era of antimicrobial re s i s tance. P o s tgrad M ed. 2010;122(6):7-15.
doi:10.3810/pgm.2010.11.2217
4. Kande S , P atro S , P anigrahi A, Khora P K, P attnaik D. P revalence of uropathogen s  and
their antimicrobial re s i s tance pattern among adult diabetic patient s . Indian J  P ublic
Health. 2021;65(3):280-286. doi:10.4103/ijph.I JP H_1413_20
5. Paul R. S tate of the Globe: Ri s ing Antimicrobial Re s i s tance of P athogen s  in Urinary
Tract Infection. J  Glob Infect Di s . 2018;10(3):117-118. doi:10.4103/jgid.jgid_104_17
6. Simmering J E, Tang F , Cavanaugh J E, P olgreen LA, P olgreen PM . The Increa s e in
Hosp italization s  for Urinary Tract Infection s  and the A ss ociated Co s t s  in the United
State s , 1998-2011. Open F orum Infect Di s . 2017;4(1):ofw281. P ubli s hed 2017 F eb 2 4.
doi:10.1093/ofid/ofw281
7. An g er J , Lee U, Ackerman AL, et al. Recurrent Uncomplicated Urinary Tract Infections
in Women: AUA/CUA/ S U F U Guideline. J  Urol. 2019;202(2):282-289.
doi:10.1097/ J U.[ADDRESS_149586] Infection s . ClinicalTrial s .gov.
https ://clinicaltrial s .gov/ct2/ s how/re s ult s /[STUDY_ID_REMOVED]?term=Complicated+Urinary+T r
act+Infection s +outcome s &dra w =2&rank=5. Updated J an 11, 2022. Acce ss ed M ay 12,
2023 .
UPH-STD-05-01
Vers i on:  [ADDRESS_149587] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 37 o f  44
Page 37 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
18. APPEND I CE S
Appendix I. Treati n g In ve s tigator Q u e s tio nn aire
*To be completed in reference to bot h  urine P CR and C& S  re s ult s
Which te s t re s ult were you
provided with to u s e for your
patient care?
Which of following de s cribe s
your patie n t’ s  cUTI event?
What wa s  the clinical outcome of
your patie n t care at EO S  vi s it?
What wa s  the microbiological
outcome o f  your patient care at
EOS vi s it? (eradication of the
pathogen s  identified at ba s eline)
Based on provided diagno s tic te s t
result s  (PCR or C& S )
1. Availability of diagno s tic
result s  (i.e. acceptable turnaround
time to re d uce the u s e of empi[INVESTIGATOR_132331]- s pectrum antibiotic s )
2. Comprehen s ibility of
diagno s tic re s ult interpretation
UPH-STD-05-01
Vers i on:  [ADDRESS_149588] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJH☐Urine P CR Re s ult
☐Urine C& S  Re s ult
☐M onomicrobial infection
☐Polymicrobial infection
☐Recurrent infection
☐No infection
☐Clinical improvement
(A complete resolution or significant improvement of signs or symptom s  of
cUTI)
☐Clinical failure
(Your patient has 1) on-going A Es/ SA Es at E OS  and/or 2) persistent c U TI
symptoms and/or 3) developed ne w  symptoms of c U TI)
☐Indeterminate
(if the outcome w as other than clinical improvement or clinical failure.
Provide reason: ____________________________________________ _ _)
☐N/A
(if the subject did not complete the study visit)
☐Eradication
☐Per s i s tence
☐Emergent infection (new infection or s uper-infection )
☐Other ( s pecify: ____________________________ _)
Score
(5) – Excellent
(4) – Good
(3) – Acceptable
(2) – Need s  improvement
(1) – Unacceptable
(5) – Excellent
(4) – Good
(3) – Acceptable
(2) – Need s  improvement
(1) – Unacceptable
Page 38 o f  44
Page 38 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
3. Efficie n cy of diagno s tic
proce ss  (i.e. u s efulne ss  of the te s t
result s  in clinical deci s ion
making)
4. Overall s ati s faction with the
assigned diagno s tic te s t
5. Impact on patient care:
Compared to the comparator te s t,
clinical deci s ion made with the
assigned te s t re s ult ha s  yielded
better patient clinical outcome
Total S core:(5) – Excellent
(4) – Good
(3) – Acceptable
(2) – Need s  improvement
(1) – Unacceptable
(5) – Very s ati s fied
(4) – M ore than s ati s fied
(3) – S ati s fied
(2) – P artly s ati s fied
(1) – Not at all s ati s fied
(5) – S trongly agree
(4) – Agree
(3) – Neither agree nor di s agree
(2) – Di s agree
(1) – S trongly di s agree
/25
Score Interpretation:
Weighted s ummary s core s  in each criterion range from 1 to 5, with higher s core s  indicating
greater dia g no s tic and therapeutic val u e of the s pecified te s t. A higher total s core indicate s  bette r
clinical utility of the a ss igned te s t than the comparator te s t.
Total s co r e will be inte r p r eted a s  follow s :
The te s t method with a total s core:
≥ 20 = Good clinical utility
10 – 19 = M oderate clinical utility
0 – 9 = P oor clinical utility
Appendix I I . Uri n e S am p le Collectio n
- Early morning urine s pecimen s  (‘fir s t void s pecimen’) are preferred, however routine or
random s ample s  are acceptable.
- Upon s ample collection, immediately refrigerate the s pecimen and s ubmit to the central
laborator y  within 24 hour s  of collection (maintain at 2-8 ºC when tran s porting).
- If tran s po r tation to the central laboratory i s  expected to exceed 24 hour s , whole cup s  of urine
specimen mu s t be frozen. However, for expedited P CR te s t proce ss ing, aliquot 1mL of urine
into two* s eparate 1.5mL Non- S tick RNa s e- F ree microfuge tube s  labeled with patient
informati o n. Aliquoted tube s  (for P CR te s ting) and the remaining urine s pecimen in the cup
(for C& S  te s ting) mu s t be place in t h e freezer (< -20 ⁰C).
UPH-STD-05-01
Vers i on:  [ADDRESS_149589] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 39 o f  44
Page 39 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
*One tube is for immediate proce ss ing on the following work day and the other i s  a backup in
case te s ting need s  to be repeated.
Method s
Clean-
catch
Mids treamSupplies
- Ster ile 90 mL containe r
- ToweletteInstruction
Patient instructions:
Step 1. Wash and dry your hands thoroughly.
Step 2. Remove the container lid and set it aside. D o not touch inner surface s .
Step 3. Cleanse your urogenital area ( “lo w er parts”) w ith the to w elette provided.
Women: Wipe from front to back bet w een the folds of skin.
Continue to hold the skin fold apart until the urine sample is
collected
Men: Wipe the tip of the penis (if un-circumcised, retract the foreskin).
Continue to hold the foreskin back until the urine sample is collected
Step 4. P ass a small amount of urine into the toilet bo w l.
Step 5. U rinate into the container until the container is 1/2 to 2/[ADDRESS_149590] the lid and tighten firmly.
Step 8. Wash and dry your hands thoroughly.
Note: T he c o llecto r  mu s t NO T  combine u r ine collected f r om s epa r ate void s  to c r eate one
specimen of s ufficient volume, unde r  any ci r cum s tance s .
Appendix I II . Device sp ecificatio n : p at h oge n  target s  a nd  C q  ra n ge s , a n ti b iotic s  re s i s tance
gene s  a n d Cq  ra n ge s
Pathogen ta r get s
· Candi d a albican s , glabrata, parap s ilo s i s , tropi[INVESTIGATOR_132332] s
· Chlamydia trachomati s
· Citrobacter freundii/braakii
· Citrobacter ko s eri
· Enterococcu s  faecium, faecali s
· Es cherichia coli
· Gardnerella vaginali s
· Kleb s iella pneumoniae/oxytoca
· M ycopla s ma genitalium
· Nei ss e r ia gonorrhoeae
· Proteus mirabili s , vulgari s
· Ps eudomona s  aerugino s a
· Serratia marce s cen s
· Staphylococcu s  (coagula s e negative: epi[INVESTIGATOR_132333] s ,
haemolyticu s , lugdunen s i s , s aprophyticu s )
· Staphylococcu s  aureu s
· Staphylococcu s  s aprophyticu s
UPH-STD-05-01
Vers i on:  [ADDRESS_149591] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHCq range s  fo r  pathogen detection
Critically Hig h : 10.000 – 21.000
High : 22.000 – 26.000
Med i u m: 27.000 – 28.000
Low : 29.000 – 32.000
Negative : 40.000 – 33.000;
09.000 – 1.000
Page 40 o f  44
Page 40 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
· Strept o ccoccu s  agalactia (group B)
· Strept o coccu s  pyogene s
· Trichomona s  vaginali s
· Ureapla s ma urealyticum
· Acinet o bacter baumannii
Antibiotic r e s i s tance gene s
· Cla ss  A ß-lactama s e; blaK P C
· Cla ss  A ß-lactama s e; CTX- M -Group1
· Cla ss  B metallo-ß-lactama s e; blaND M
· Cla ss  D oxacillina s e OXA-48
· Cla ss  D oxacillina s e OXA--51
· dfr (A 1 , A5), s ul (1,2) probe s  ( S ulfamethoxazole and
trimethoprim)
· ermB, C; mefA
· IM P, N D M , VI M  Group s  (Carbapenem)
· M RS A * M ec-A
· PER-1/VEB-1/GE S -1 Group s  (ESBL)
· qnrA1, A2
· qnrBCq range s  fo r  r e s i s tance gene
identification
Positive: 10.000 – 31.000
Negative : 32.000 – 40.000;
1.000 – 9.000
· qnr S
· tetB, tet M
· VanA, VanB (Vancomycin)
· ACT, M IR, F OX, ACC Group s  (Beta Lactam s )
Appendix IV. Com p arator te s t re su lt s
1. PCR Po s itive te s t re s ult: li s ting s  of detected microorgani s m s  and antimicrobial s en s itivit y
(sample)
UPH-STD-05-01
Vers i on:  [ADDRESS_149592] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 41 o f  44
Page 41 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
2. PCR Negative te s t re s ult ( s ample)
UPH-STD-05-01
Vers i on:  [ADDRESS_149593] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 42 o f  44
Page 42 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
UPH-STD-05-01
Vers i on:  [ADDRESS_149594] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 43 o f  44
Page 43 of 44
Doc Lab Inc. / P r otocol Numbe r  22-UPHUV-01
Advarra IRB Approved Version 0, Date: 12 May 2023 / Pro00071764
3. Urine C& S  P o s itive te s t re s ult: li s ting s  of detected microorgani s m s * and antimicrobial
sensitivity ( s ample)
*The pre s e n ted s ample te s t report demon s trate s  a mere example of detectable microorgani s ms.
4: Urine C& S  Negative te s t re s ult ( s ample)
UPH-STD-05-01
Vers i on:  [ADDRESS_149595] i ve  Date:  06/23/2023
Docu m en t R e f: WQAPR-C 9 AUZ-GYNVC - SHXJHPage 44 o f  44
Page 44 of 44
Signature  [CONTACT_132378]:  WQAPR-C9AUZ-GYNVC-SHXJH
Signer
Roel  Chavez
Email:  [EMAIL_2657]
Shared  via  link
Sent:
Viewed:
Signed:
[CONTACT_132381]  K  Huard
Email:  [EMAIL_2658]
Shared  via  link
Sent:
Viewed:
Signed:Timestamp
23 Jun  2023  21:12:13  UTC
26 Jun  2023  13:42:25  UTC
27 Jun  2023  15:38:00  UTC
23 Jun  2023  21:12:13  UTC
23 Jun  2023  21:26:06  UTC
27 Jun  2023  17:02:49  UTCSignature
[CONTACT_132379]:  [IP_ADDRESS]
Location:  Portland,  United  States
IP address:  [IP_ADDRESS]
Location:  Austin,  United  States
Document  completed  by  [CONTACT_132374]:
27 Jun  2023  17:02:49  UTC
Page  1  of  1
Signed  with  PandaDoc
PandaDoc  is  a  document  workflow  and  certified  eSignature
[CONTACT_132380]  40,000+  companies  worldwide.